Entities

UI Investissement is a French private-equity and venture-capital manager financing startups, small and medium-sized businesses and mid-market companies throughout their development. Its strategies span growth and buyout capital, innovation investing and sector consolidation, with regional investment teams supporting company expansion, acquisitions and ownership transitions. Its innovation funds commercialise research in industrial technology, environmental sustainability, health and life sciences through partnerships with research institutions and industrial companies. Pertinence Invest is its industrial deep-technology fund family, while other strategies include regional and healthcare investment programmes. The own legal notice identifies UI Investissement SAS, registered in Paris under company number 417810538, as the management company. The website publishes a combined investment and support roster; publication does not establish that every person is employed by the same legal affiliate.

Desmond Lim is Member, SEEDS Investment Panel at SEEDS Capital, as listed in its official investment panel page updated2July2026 and reviewed7October2026. The panel identifies him as DeputyChiefExecutiveandCTOoftheNationalSpaceAgencyofSingapore; thispublicagencyroleisdistinctfromSEEDSstaffemployment. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Choo Heng Tong is Member, SEEDS Investment Panel at SEEDS Capital, as listed in its official investment panel page updated2July2026 and reviewed7October2026. The panel identifies him as ChiefExecutiveOfficerofSGGrowthCapital and ExecutiveVicePresident/ExecutiveCommitteememberoftheEconomicDevelopmentBoard. Those areparent/publicagencyappointments, notan assumedSEEDSCEOtitle. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Cindy Khoo is Member, SEEDS Investment Panel at SEEDS Capital, as listed in its official investment panel page updated2July2026 and reviewed7October2026. The panel identifies her as DeputyChairmanofparentSGGrowthCapital and ManagingDirectorofEnterpriseSingapore, distinct from SEEDSoperatingemployment. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Ken Phua is Member, SEEDS Investment Panel at SEEDS Capital, as listed in its official investment panel page updated2July2026 and reviewed7October2026. The panel identifies him as GlobalCEOofXGTech; panelmembership is an investment-review affiliation rather thanSEEDSstaffemployment. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Lee Kheng Nam is Chairman, SEEDS Investment Panel at SEEDS Capital, as listed in its official investment panel page updated2July2026 and reviewed7October2026. The own currentpanel also identifies him as VenturePartner atGraniteAsiaCapital. The undatedattachedbiography describes earlierVertex/NatSteel/MinistryofNationalDevelopment experience and uses theformerGGVbrand; those historical details do notsupersede currentGraniteAsia naming. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Danny Chiam is Investment Manager at SEEDS Capital, as listed in its official investment team page updated2July2026 and reviewed7October2026. SEEDS Capital co-invests alongside privateventurecapitalpartners into early-stageSingaporetechnologycompanies, within the government-backed StartupSGEquity framework. The published team page establishes this specificcurrentrole; individual sectorassignments orpersonal checks are not inferred. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Sean Keng Rui Chia is Investment Manager at SEEDS Capital, as listed in its official investment team page updated2July2026 and reviewed7October2026. SEEDS Capital co-invests alongside privateventurecapitalpartners into early-stageSingaporetechnologycompanies, within the government-backed StartupSGEquity framework. The published team page establishes this specificcurrentrole; individual sectorassignments orpersonal checks are not inferred. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Clement Chua is Investment Manager at SEEDS Capital, as listed in its official investment team page updated2July2026 and reviewed7October2026. SEEDS Capital co-invests alongside privateventurecapitalpartners into early-stageSingaporetechnologycompanies, within the government-backed StartupSGEquity framework. The published team page establishes this specificcurrentrole; individual sectorassignments orpersonal checks are not inferred. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Hui Shi Foo is Senior Investment Manager at SEEDS Capital, as listed in its official investment team page updated2July2026 and reviewed7October2026. SEEDS Capital co-invests alongside privateventurecapitalpartners into early-stageSingaporetechnologycompanies, within the government-backed StartupSGEquity framework. The published team page establishes this specificcurrentrole; individual sectorassignments orpersonal checks are not inferred. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Jacqueline Chia is Deputy General Manager at SEEDS Capital, as listed in its official investment team page updated2July2026 and reviewed7October2026. SEEDS Capital co-invests alongside privateventurecapitalpartners into early-stageSingaporetechnologycompanies, within the government-backed StartupSGEquity framework. The published team page establishes this specificcurrentrole; individual sectorassignments orpersonal checks are not inferred. SEEDS Capital PteLtd is distinct from its currentfundmanagerSGGrowthCapital PteLtd. Officialnamedportraitverified; appointmentdateundisclosed.

Bradley Nelson is a co-founder and mentor of Nanoflex Robotics and an ETH Zurich professor associated with the Multi-Scale Robotics Lab. His work in magnetic navigation and microrobotics underpins the company’s technology. The company lists him as Mentor and Co-Founder; its primary founding announcement names him with Curran and Chautems in2021.

Chanel Allen-Megahey is published as CRO in Nanoflex Robotics’ current leadership directory. She has20years of regulatory and clinical experience and a PhD from Queen’s University Belfast. The exact CRO acronym is preserved without guessing whether it means regulatory, risk or revenue officer.

Christophe Chautems co-founded Nanoflex Robotics and formerly served as CTO, developing compact magnetic navigation and steerable catheter technology from his ETH Zurich research. His first-person final-day announcement confirms he stepped down from executive duties and transitioned to a Non-Executive Director role. The2025 company study still identified him as CTO; that historical appointment is retained in this biography rather than treated as current.

Matt Curran is CEO and co-founder of Nanoflex Robotics, an ETH Zurich spin-off developing magnetic endovascular robotic navigation. He brings more than20years of commercial experience at Medtronic and an MBA from Edinburgh Business School. The current own leadership directory identifies his role, and Innosuisse’s January2026 announcement independently confirms it when appointing him to its Innovation Council.

Per Vegard Nerseth is an independent non-executive director of Nanoflex Robotics. He previously led CMR Surgical as CEO and spent ten years as Global Head of ABB Robotics. Nanoflex announced his appointment August5,2024; its current leadership directory retains the exact independent director title.

Nanoflex Robotics AG is a Swiss ETH Zurich spin-off founded in2021 by Matt Curran, Bradley Nelson and Christophe Chautems. It develops the Remote Intervention System, combining a mobile electromagnetic field generator, ultra-flexible magnetically steerable guidewires and catheters, robotic advancement and a control console for endovascular procedures. Its longer-term neurovascular application is remote mechanical thrombectomy for ischemic stroke. Current development initially targets bedside peripheral vascular interventions, followed by control-room and teleoperated procedures. In2025 the company reported preclinical animal thrombectomy across the Atlantic and within Switzerland, plus porcine peripheral stenting; animal feasibility is distinct from human clinical efficacy. The European Commission’s current REACT project states clinical validation, regulatory approval and manufacturing readiness remain project objectives for2026–2028. The2023 first-in-human/FDA submission timetable was a plan, and ISO13485 quality-system certification does not establish device marketing approval. No current FDA clearance or CE marketing authorisation is established by the reviewed primary sources. The platform is described as AI-compatible and a Brainomix collaboration is developing AI-assisted navigation; the research partnership is not an investment. Public leadership includes CEO/co-founder Curran, mentor/co-founder Nelson, independent director Per Vegard Nerseth and CRO Chanel Allen-Megahey. Chautems announced his transition from CTO to non-executive director. A February2023 Series A secured an initial USD12million, led by Ascend Capital Partners with Kinled Holding and Mountain Labs. Innosuisse grants received in2023 comprised CHF2.5million and CHF400,000. A June2026 EIC blended-finance selection announced a EUR2.5million grant and EUR10million proposed equity; CORDIS later records a signed EUR2,498,971.85 REACT grant, while cash disbursement and equity closing remain unverified.

Judy Yan is named as a DHVC managing director in its January2020archived official directory. A native named portrait is preserved from that official page. Her present2026employment and any separate Yan-branded manager are not inferred from a historical directory or name match.

Shoucheng Zhang was a Stanford theoretical physicist and a co-founder of Danhua Capital. The2014and2016fundfilings identify him as a managing member or managing director of the general partner. His scientific work included topological quantum materials. Stanford’s obituary confirms he died onDecember1,2018; no current manager or company director role is asserted.

Kevin Ding is named as a DHVC partner in the firm’s January2020archived official team page. His historical investing interests included robotics, artificial intelligence and technology businesses. That archived title is not independently confirmed as his current2026employment.

Andrew Gu, whose legal name is Anjia Gu, co-founded Danhua Capital. The current March2026SEC adviser filing names him as managing member of Danhua Capital Management LLC. His historical official DHVC profile identifies him as founding managing partner, with a background in electrical engineering and applied physics atStanford and earlier sensor-technology work. His current legal manager role is independently established rather than inferred solely from the archived2020directory.

Sabrina Xiong’s accessible Ascend Capital Partners biography identifies her as a vice president who joined in 2007, with more than twenty years in accounting, audit, investment and financial advisory work. Her sector experience includes automotive components, healthcare and technology/media/telecommunications. She previously studied and worked in the UK, including JPMorgan in Bournemouth and Leapman Weiss in London. She has a master’s in Investment and Finance from Brunel University and professional ACCA membership. Her name is omitted from the current six-person team index; this published legacy role is not asserted as current employment or as a confirmed departure.

Vinern Leow joined Ascend Capital Partners in 2024 and covers healthcare and mobility investing, bringing trade-finance, treasury and product-commercialization experience. Previously he spent eight years in Citi’s New York and Singapore transaction-banking businesses, progressing through corporate-advisory and product-management positions. Originally from Malaysia and based in Singapore, he has also lived in the United States, Australia and the United Kingdom. He earned a BS from Boston College.

Matthew Mu is an Ascend Capital Partners vice president focused on technology companies with cross-border mobility and medtech opportunities. He joined in 2010, worked on international M&A and private-equity projects, and assisted CASIC’s acquisition of Luxembourg sensor company IEE. Previously he worked for two years as a management consultant at Adfaith. His strengths include market research and helping international companies commercialize in China. He has a master’s in Finance and Economic Policy from the University of Glasgow.

Colin Powrie is an Ascend Capital Partners vice president covering automotive and healthcare investments, deal execution, strategy and portfolio business development. A chartered accountant, he qualified at Deloitte in London and advised on M&A and IPO transactions. His own biography describes more than eleven years of company-advisory experience and work across the UK, Continental Europe, India, Hong Kong and China. He speaks English, Mandarin and Cantonese.

Elaine Mo is an Ascend Capital Partners vice president managing healthcare investments. Her own biography describes more than six years of management and financial consulting experience, previously at PwC and boutique firms, covering financial reporting, strategic planning, process improvement and change management. Her clients included U.S. government bodies, utilities and growth businesses. She previously worked part-time as an Ascend analyst in Beijing and participates in U.S. startup and investor communities. No education or specific personal investment is inferred.

Jian(Jerry)Hong is Ascend Capital Partners’ CEO. He previously served as a SAIC Europe vice president, responsible for European business development and investment, and has more than twenty years of automotive, cross-border M&A and technology-investment experience. He holds an MBA from Washington University’s Olin Business School and an undergraduate computer-science/technology degree. Aiforia’s current issuer biography names the same professional Jerry Jian Hong, its board member since 2022, Ascend CEO and managing director of Ascend Tapio/Artemis S.a.r.L since 2020, with the same SAIC Europe background. Corporate board affiliations do not imply a personal company subscription.

Ascend Capital Partners is the cross-border medtech and mobility investor operating at ascend-cp.com, founded by Kin Lai Monita Au in Beijing in2002 with a public team spanning Luxembourg, Hong Kong, China, the United States and Singapore. Its own current site says it invests its own capital and works with founders on governance, operations, international market entry and commercialization. It focuses on early-stage differentiated deep technologies and complementary platform businesses in Europe and Asia that can expand internationally. Its AI, healthcare and neuroscience-related portfolio includes pathology-AI company Aiforia, contactless-monitoring developer Neteera, tomographic ultrasound company PIUR Imaging, endovascular stroke-robotics developer Nanoflex Robotics, digital-pathology scanner company Grundium, semiconductor-materials company Canatu and autonomous/teleoperated mobility businesses. Current native biographies name founder and chairwoman Kin Lai Monita Au, CEO Jian(Jerry)Hong and four vice presidents; a separate accessible Sabrina Xiong biography is qualified as a published legacy affiliation because the current team index does not list her. Aiforia’s current official board profile independently confirms Jerry Jian Hong as CEO of Ascend and managing director of Ascend Tapio/Artemis S.a.r.L since2020. This confirms affiliated Luxembourg investment-company activity, without establishing those names as LP venture funds or publishing an exact current subscribing vehicle for each deal. The platform’s own April2023 announcement of a planned up-to-EUR60million deployment and cumulative investment-return figures are not closed fund sizes. No externally raised LP fund close is verified in retrieved primary sources. This firm is distinct from Seattle’s Ascend/Ascend.vc, St.Louis Ascend Venture Capital, U.S. healthcare private-equity Ascend Partners/Ascend Capital Partners and other similarly named funds. Their reported USD791million fund, SEC LP vehicles and personnel are not transferred to this own-capital Luxembourg/Hong Kong platform. Investments are institutional relationships; board positions and founder ownership do not establish individual cash checks.

Kin Lai Monita Au is Ascend Capital Partners’ founder and chairwoman. A Hong Kong native, she spent nine years at Arthur Andersen in New York before establishing her own accounting firm there in 1992. She founded Ascend in Beijing in 2002 and subsequently co-founded Best Genetics Group with her husband to improve livestock health and food safety. Older own articles call the same founder Monita Mo, while Aiforia’s 2021 offering circular identifies her as Monita Au Kin Lai. These are qualified founder-name variants, not separate investor records; her current own role is chairwoman, while Jerry Hong is CEO.

Prompt Shields develops software that discovers, monitors and governs enterprise use of artificial intelligence. Its Atlas AI platform identifies unregistered AI tools and vendor AI features, connects use cases with accountable owners and risk assessments, and builds an inventory for security and governance teams. A unified AI gateway tracks model requests, costs and latency while applying controls for prompt injection, sensitive-data exposure and organizational policies. The company also offers employee-facing AI assistance, agent security tools, developer SDKs and governance consulting. It operates from Norway and the UK and offers self-hosted deployment.

TIBEAY BioSciences is a Netherlands-based clinical-stage biotechnology company developing an investigational treatment for acute traumatic brain injury. Its lead small molecule, ronopterin, is designed to inhibit inducible nitric oxide synthase and reduce secondary neurological damage after the initial trauma. The company is preparing a European multicenter Phase 3b study in patients with severe traumatic brain injury, alongside manufacturing and regulatory work needed for a potential European marketing application. The medicine is in clinical development and is not an approved treatment. The financing issuer is TIBEAY Biosciences B.V., based in Nijmegen.

Senior investment manager for Health at Oost NL, participating in biotechnology investments including TIBEAY BioSciences.

Biotechnology executive who announced taking the TIBEAY CEO role after its April 2026 financing.

Quality-systems consultant supporting clinical trial execution.

Enterprise software engineer focused on security and privacy.

Physician and clinical researcher working on therapies for traumatic brain injury.

Clinical-trial operations specialist supporting TIBEAY’s Phase 3 program.

Enterprise software entrepreneur and technology executive with more than 15 years of experience.

Enterprise software and security engineer with more than 20 years of experience; also published as a Microsoft principal engineer.

Cybersecurity adviser with former HSBC and NHS CISO experience.

AI engineer and former venture investor and management consultant with an NTNU industrial-economics degree.

Former Crayon managing partner and AI lead advising on enterprise AI adoption.

Consultant with intensive-care and clinical-site management experience.

Navam Capital is a Kolkata venture-capital firm making seed and early-stage investments in frontier technology and science-driven businesses. It backs Indian companies developing intellectual property for global markets in aerospace, semiconductors and advanced electronics, climate technology, robotics, industrial automation, biotechnology and advanced materials. The firm combines investment, scientific and operating experience to help founders commercialize research and build industry relationships. Its regulated investment manager is Navam Investment Advisors LLP.

Riceberg Ventures is a global venture-capital firm backing pre-seed and seed companies commercializing deep technology. Its investments span space technology, medical technology and life sciences, clean energy, cybersecurity, future computing, and foundational AI and robotics. Its partners support scientific and engineering founders through early product development and international expansion, and the firm co-founded the Kicksky Space Labs accelerator.

Tiemo Steinmann is a memodio-affiliated contributor to the2025 preliminary MEMODIO_APP@CARE clinical-trial publication. The primary Alzheimer’s &Dementia abstract spells out his full name and company affiliation, and the European Psychiatry abstract discloses his employment atmemodio GmbH. His published contribution concerns a12-week multidomain app intervention for cognitive impairment. This establishes a dated research-team relationship without inventing a current2026 managerial title, additional qualifications or a personal financing participation.

Patrizia Mecocci is a professor of internal medicine and gerontology at the University of Perugia and a member of memodio’s scientific advisory board. Her primary university directory identifies responsibility for theGerontology andGeriatrics section. The university’s biogerontology research profile describes work on ageing, neurodegenerative disease, dementia biomarkers and digital methods for diagnosis and follow-up of cognitive disorders. The company associates her with geriatric expertise in its multimodal digital programme. Her advisory role is separate from university and hospital appointments.

Valentina Weil is a memodio-affiliated clinical-research collaborator and corresponding author in the2025 published preliminary MEMODIO_APP@CARE trial abstract. The publication identifies memodio GmbH inPotsdam as her institutional affiliation, and the associated European Psychiatry abstract discloses company employment. Her work concerns evaluation of a multidomain app-based intervention for patients with cognitive impairment. The published2025 affiliation is retained with its date qualification; exact current job title, wider career and an authentic portrait remain unverified.

Francesca Mangialasche is a geriatrician and dementia-prevention researcher on memodio’s scientific advisory board. Karolinska Institutet’s current biography identifies her as a senior researcher inNeurobiology, Care Sciences and Society and records doctoral training atKarolinska. Her research covers Alzheimer’s disease, dementia, geriatric epidemiology and multidomain lifestyle interventions. Karolinska’s primary WW-FINGERS material also identifies her scientific coordination work in the international network. The company’s scientific-advisor affiliation does not independently imply a personal equity investment or full-time memodio employment.

Arnim Quante is a psychiatrist and scientific advisor to memodio. The company abbreviates his name as A.Quante and identifies his work at the Friedrich von Bodelschwingh clinic inBerlin. The clinic’s own2026 programme confirms his full name and senior role directing its centre for older-person psychiatry and psychotherapy. His teaching covers dementia diagnosis, prevention and treatment and psychopharmacology in older adults. This resolves the abbreviation to Arnim rather than a guessed Andreas or Alexander namesake. The memodio role is advisory.

Daphne Teo is a historical co-founder of Engine Biosciences, identified in the contemporaneous2018 issuer announcement republished by EDBI. Nest.Bio’s current directory identifies her as a partner and NSG BioLabs CEO. Founding affiliation does not imply a current operating role at Engine. Goodman Capital’s archived May2019 primary team directory additionally identifies Daphne Teo as Co-founder and Managing Director (historical published affiliation). This Singapore firm invested its principals’ and families’ capital; the role is source-qualified historical and does not imply a currently held appointment or personal cash investment.

Gereon Nelles is a neurologist and scientific advisor to memodio. Primary professional-association material establishes his neurological clinical background; the company lists him on its scientific advisory board. The German Clinical Trials Register identifies him at NeuroMed Campus inCologne as the scientific contact for the MEMODIO_APP@CARE exploratory trial, with memodio GmbH as sponsor. He is a named author of published preliminary trial results. His clinical-research and advisory relationships are distinguished from company employment and from any unproven personal investment.

Hu Li is an Engine Biosciences scientific founder and adviser. His Mayo Clinic research uses systems pharmacology, regulatory-network analysis and machine learning to support individualized medicine.

Martina Heer is a nutritional-physiology specialist named on memodio’s scientific advisory board. The company identifies her contribution in nutrition research, while a primary university biography records doctoral training in nutritional science and research at the German Aerospace Center on space physiology and nutrition. She has contributed to research on metabolism and nutrition in unusual physiological conditions. Her company listing supports an advisory role in the app’s nutritional component; the older Bonn institutional title is retained as company-published background rather than automatically assigned as a current university appointment.

Prashant Mali is an Engine Biosciences scientific founder and adviser. His UC San Diego research covers synthetic biology, regenerative medicine and tools for gene- and cell-based therapies, including CRISPR genome engineering.

José Iglesias is an Engine Biosciences clinical scientific adviser. His oncology-development experience includes HiberCell, Boston Biomedical and Biothera, including translational medicine and early clinical programmes.

Stefan Schneider is a movement and neuroscience researcher on memodio’s scientific advisory board. The German Sport University Cologne identifies him within its Institute of Movement and Neurosciences. His primary research biography describes study of neurocognitive and neuroaffective performance in extreme environments, and the relationship between physical exercise, brain activity and health. His training includes sport science and doctoral research in sensorimotor adaptation. The memodio affiliation is scientific advice on a multimodal intervention rather than an assumed full-time company appointment.

Elke Kalbe is a medical-psychology and neuropsychology professor named on memodio’s scientific advisory board. The University Hospital Cologne’s primary directory identifies her as head of Medical Psychology, Neuropsychology and Gender Studies. Her academic expertise is relevant to cognitive assessment and psychological aspects of neurological disease. The company lists her advisory contribution to its digital cognitive-health programme. The role is separate from her university employment; an advisory listing is not treated as proof of company shares or an individual financing participation.

George Trainor is an Engine Biosciences scientific adviser with experience in medicinal chemistry, discovery strategy and development of drug candidates across oncology, antivirals, neuroscience and inflammation.

James Collins is a scientific founder and founding scientific advisory co-chair of Engine Biosciences. A synthetic-biology researcher at MIT, he develops engineered biological systems with applications in infections, antibiotic discovery and cellular behaviour.

Maria Cristina Polidori is a physician and clinical ageing researcher on memodio’s published scientific advisory board. Primary professional material identifies her as professor and head of clinical ageing research at the University of Cologne. She earned her medical degree at the University of Perugia, undertook research at Massachusetts General Hospital and Boston University, specialised in geriatrics and completed academic qualification inGermany. Her work focuses on ageing mechanisms, healthy ageing and the care of older patients. Her company affiliation is advisory, not an employment or personal-investment claim.

Nicholas A. Saccomano, PhD, is a Modulo Bio board director announced inJuly2025 and previously disclosed inNovember2024. The issuer describes four decades of drug discovery experience, including leadership at OnKure, Pfizer, Array BioPharma and SomaLogic. He earned a Columbia organic chemistry PhD and a SUNY Buffalo bachelor’s degree. Those career titles are source-dated to the announcement rather than asserted as current2026 employment. Retained earlier biography: Nicholas A. Saccomano advises Engine Biosciences on drug discovery. His earlier positions included Pfizer’s Boulder research-site leadership, chief scientific officer at Array Biopharma and chief technology officer at SomaLogic. He holds a Columbia organic-chemistry doctorate.

Joy Ho is last published as an Engine Biosciences board observer representing EDBI in April2026. Her background includes healthcare investing, a lung-cancer programme at Genome Institute of Singapore, molecular-engineering research and Genentech manufacturing. Current EDBI primary directory additionally lists her as Associate Principal in the Healthcare investment team; the earlier Engine Biosciences observer affiliation and its historical qualification remain preserved.

Paul Zimmermann is a software engineer and co-founder of memodio, responsible for technical leadership and app development. The company’s current founder biography describes his involvement from the initial concept to the finished product, with emphasis on reliability, usability and support for patients and families. Its2023 funding announcement identifies him as an HPI software engineer. He formed the company with physicians Doron Stein and Felix Bicu. No additional corporate appointments or personal investment amounts are inferred from his founding role.

Ali Farahanchi is last published as an Engine Biosciences director in April2026. The directory identifies his managing-director affiliation with Camford Capital and prior research and consulting in semiconductor and healthcare industries. His graduate training includes MIT and Chicago.

Felix Bicu is a physician, memory trainer and co-founder of memodio. His own company biography describes work on cognitive activation and support for family caregivers, drawing on clinical experience and care for a grandfather with dementia. The2023 issuer funding announcement also identifies him as founder and public-relations contact. He is affiliated with memodio in the2025 MEMODIO_APP@CARE research abstract, connecting the company’s product development with clinical investigation. His exact broader clinical speciality and current management title are not expanded beyond the primary sources.

Doron Benjamin Stein is a physician, co-founder and chief executive of memodio GmbH. The company’s legal disclosure identifies Dr.Doron B.Stein as its authorised representative; its first financing announcement names him CEO. He helped develop the app’s digital, non-drug approach to mild cognitive impairment and early dementia and contributed to the white paper on care for early Alzheimer’s disease. His founder biography connects his interest in earlier cognitive care to dementia in his family. The company was founded with Felix Bicu and software engineer Paul Zimmermann inPotsdam inDecember2021.

memodio GmbH is a Potsdam digital-health company developing a multimodal mobile therapy for people with mild cognitive impairment and mild dementia. Founded inDecember2021 as a spin-off of the University of Potsdam and Hasso Plattner Institute, it combines cognitive exercises, physical activity, nutritional guidance, risk-factor education and support for everyday routines and social participation. The founders are physicians Doron Benjamin Stein and Felix Bicu and software engineer Paul Zimmermann. Its registered identity is Potsdam HRB36139P, VATDE351312294, with offices atPotsdamTransfer, August-Bebel-Straße89. Its native instructions identify the app as an MDR ClassI CE-marked medical device. The statutory-insurer association’s official2025 DiGA report records admission onDecember27,2025 with status Erprobung, meaning provisional listing; the company’s current pages describe prescription and German statutory-health-insurance reimbursement. A live BfArM record requires JavaScript and its full current entry was not retrievable during this audit, so permanent listing is not asserted. A registered exploratory MEMODIO_APP@CARE trial studied mild cognitive impairment and mild dementia; published2025 interim findings concern cognition in a subset and do not establish a dementia cure or universal clinical benefit. Its direct neuroscience relevance lies in cognitive-health software and digital therapy; an independent general-purpose AI platform is not claimed. Primary funding includes a EUR400,000 first angel round announcedFebruary2,2023 and a Companisto member-network campaign recorded as endedMay6,2026 with EUR1,152,465. The company also publicly discloses research and innovation grant programmes, whose cash totals and settlement dates are not published.

Karsten Witt is last published as Engine Biosciences’ clinical-development leader in April2026. His oncology and inflammatory-disease experience includes Black Diamond Therapeutics, Array Biopharma, OSI, Gilead, NeXstar and Amgen. He earned his medical degree in Copenhagen.

David M. Epstein was an Engine Biosciences scientific adviser from2017 and additionally served in R&D leadership from2023. His background included Black Diamond Therapeutics, Duke-NUS and OSI Pharmaceuticals. Engine subsequently publicly announced his death in2026; his affiliation here is historical, with exact death day undisclosed.

Robert Abraham is last published as Engine Biosciences’ chief scientific officer in its April2026 directory. He previously led cancer biology at Odyssey Therapeutics, served as Vividion CSO and held oncology research leadership at Pfizer and Wyeth.

Yaron Turpaz joined Engine Biosciences in2018 and is last published as CIO in its April2026 directory. Earlier informatics leadership included Human Longevity, AstraZeneca, Eli Lilly and Affymetrix. He trained in bioengineering at Illinois and business at Chicago Booth.

Jeffrey Lu co-founded and leads Engine Biosciences. His earlier career included Bain and AirAsia, and founding or leadership work at Enleofen Bio, PairX Bio and travel-technology company AAE. He holds a University of Pennsylvania BA. This is the biotech entrepreneur, distinct from the a16z and Aberdeen namesakes. Goodman Capital’s archived May2019 primary team directory additionally identifies Jeffrey Lu as Co-founder (historical published affiliation). This Singapore firm invested its principals’ and families’ capital; the role is source-qualified historical and does not imply a currently held appointment or personal cash investment.

Engine Biosciences is a Singapore and Silicon Valley biotechnology company applying machine learning and experimental genetics to discover precision oncology medicines and patient-selection biomarkers. Its NetMAPPR network-biology platform combines computational analysis with data from the CombiGEM combinatorial CRISPR system, enabling experimental tests of predicted genetic interactions. The work includes synthetic-lethal cancer targets and preclinical therapeutic programmes; these are research and development activities, not approved cancer treatments. The website’s legal notice identifies Engine Biosciences Pte Ltd and its affiliate Engine Biosciences Inc. Investor EDBI’s contemporaneous 2018 announcement dates the business’s founding to2015. The current October2026 homepage remains active but no longer publishes the team or programme directory. The latest recovered original directory, archived April16,2026, names20 people across management, board, board observers and scientific advisers. It identifies co-founder Jeffrey Lu as CEO, Robert Abraham as CSO and Yaron Turpaz as CIO; their roles are last confirmed in that directory rather than assumed from a withdrawn current roster. Historical co-founder Daphne Teo is separately documented in the2018 announcement. David M. Epstein’s archived interim R&D role is marked historical because the company subsequently announced his death. Scientific founders and advisers include Timothy Lu, James Collins, Prashant Mali, Hu Li and Martin Kampmann. Three independently documented completed financings are retained: USD10M seed January31,2018; USD43M SeriesA May26,2021; and an additional USD27M SeriesA extension October31,2023. The2023 issuer reports USD70M total SeriesA and USD86M cumulative financing; neither aggregate is an extra round, and an unexplained difference from individually announced rounds is not inferred as cash. Secondary2026 financing reports remain pending primary filing or issuer verification.

HCC external adviser and former Blue Cross and Blue Shield of North Carolina chief executive, described as CEO emeritus since 2017. His background includes law, public policy and healthcare governance; he studied at Appalachian State, Duke and Wake Forest.

Physician, hospitalist and HCC external adviser. He co-founded the Society of Hospital Medicine, held medical leadership responsibilities at Remedy, and developed clinical decision-support and natural-language-processing technology through Zato Health.

HCC external adviser with healthcare technology commercialization experience. His career includes Cigna and ActiveHealth Management, whose clinical decision-support business was acquired by Aetna. He studied economics at Trinity.

HCC external adviser with health-insurer and hospital finance experience, including Blue Cross and Blue Shield of Louisiana, Novant and Deloitte. She is a certified public accountant and studied at LSU and Tulane.

HCC external adviser and retired Duke University Health System chief financial officer. He retired in 2020; earlier experience includes Loyola, Mission and Tulane health systems and the U.S. Army. The biography spells his given name Kenneth despite a directory-heading typo.

HCC external adviser with healthcare operations and finance experience. Published career history includes Health Advocate, Magellan, Aetna, Cigna and Deloitte. He studied accounting at Notre Dame.

HCC external adviser with healthcare investing, finance and accounting experience. His published background includes Merrill Lynch private equity, health-plan financial work and an NYU MBA.

Isabelle Schein is identified by Labcorp in its March 30, 2026 healthcare AI white paper as director of new ventures and strategic alliances. She represents the corporate venture program’s role connecting scientific, technology and clinical partners; Labcorp’s November 2025 Getlabs interview also publishes this affiliation. A complete own career biography, authenticated portrait and any later promotion are not verified, so this role preserves the exact dated own publication rather than assuming a newer external-directory title.

HCC external adviser and former chief executive of Lifetime Healthcare Companies, retired in 2012. His published experience includes Excellus BlueCross BlueShield and healthcare governance. This individual is distinct from Click Therapeutics CEO David Benshoof Klein.

HCC external adviser with provider-network, bundled-payment and healthcare technology experience at Oxford, Cigna and Remedy. HCC identifies him as its ReferWell board designee. He studied technology management at MIT and chemistry at Cornell.

Megann Vaughn Watters leads Labcorp’s strategic corporate venture investing and new ventures and strategic alliances. Labcorp’s January 2026 Teal Health interview and AOA Dx’s January 2026 report identify her venture leadership; her 2026 Precision Med Tri-Conference speaker listing confirms Vice President, New Ventures and Strategic Alliances. Her published event biography describes experience identifying healthcare technologies, executing partnerships, equity investments and licensing, managing alliances and serving on venture-backed boards. Before Labcorp she was a U.S. Patent and Trademark Office medical-device patent examiner and conducted tissue-engineering research at Humacyte. She earned an MBA and a BSE in biomedical engineering at Duke University.

HCC external adviser whose published background centers on community healthcare and Open Door Family Medical Centers, with interests in access and digital care. She attended St. Lawrence and earned an MBA from Pace.

HCC external adviser with health-plan finance and operations experience. His career includes Florida Blue, Health Options and Cigna. He studied actuarial science and business at Michigan and Washington University.

Physician listed in HCC’s external advisory network. His published career spans clinical practice, health-plan and pharmaceutical operations, and leadership or advisory work with Ascension, the Advisory Board, Oliver Wyman and Vanguard.

Certified public accountant listed as an HCC external adviser. Her published career includes senior finance, administration and strategy responsibilities at Highmark and health-services board work. External affiliations are source-published career history, not a verified current employer roster.

HCC external adviser with insurance and healthcare investment experience. His published career includes leadership of Universal American and RAB Ventures. He studied law at Columbia and attended Swarthmore.

Physician and healthcare entrepreneur listed in HCC’s external advisory network. His published background covers biotechnology, medical technology and consumer health, including Celex, SolasCure, Gelmetix and Kind Consumer; he holds a Harvard MBA.

Published HCC external adviser with a healthcare insurance leadership background, including UnitedHealthcare commercial businesses and Anthem healthcare services. These outside positions are career history published by HCC, rather than independently asserted current appointments.

HCC chief financial officer appointed in 2025, corroborated by its April 2026 adviser filing. A certified public accountant, she previously worked at Goode Partners, Galen Partners and Marks Paneth and Shron, and studied accounting and taxation at NYU.

HCC principal with experience in healthcare operations, investing and investment banking. Prior roles include CareATC strategy, IMC Health, Comvest and RBC. He holds a Wharton healthcare-management MBA and a Michigan business degree.

HCC chief compliance officer, also associated with outsourced compliance provider Pillar Compliance Group. His background includes private-fund compliance at First Republic and work with ACA and Kroll. The April 2026 adviser filing corroborates his compliance responsibility.

Barbara Stegmann co-founded Living Brain with Julian Specht in2019 while studying psychology. The company’s 2022 seed press kit and2023 founder biography identify her as CEO, responsible for economic and strategic development. The current legal notice identifies Julian as managing director and the present team directory does not list Barbara; her former CEO role is therefore historical, with no assumed departure date.

Christian Gavenea is a software developer on Living Brain’s current published team, contributing to the company’s virtual-reality rehabilitation software. His current card uses Software Developer; the portrait alt refers to an earlier Junior Unity Developer title.

Dorit Posdorf is a business angel in the encourageventures network. Living Brain’s own July11,2022 seed announcement explicitly identifies her as an individual investor alongside Ina Schlie, separately from the Companisto network. Her personal allocation is undisclosed. encourageventures publishes her named member portrait; no investment by the network association is inferred from her membership.

Ina Schlie is a business angel, supervisory-board member and former SAP executive. She initiated and co-founded the encourageventures female-investor network. Living Brain’s own July11,2022 seed announcement explicitly names her personal investment and quotes her support for the company; her individual allocation is undisclosed. The network’s own named member portrait establishes her identity.

Julian Specht is managing director, Chief Scientific Officer and co-founder of Living Brain. The current legal notice confirms his management authority and the current team card identifies CSO and co-founder. He studied business psychology, gained early experience at SAP and develops scientifically grounded cognitive rehabilitation inspired by his own experience of neurological disease.

HCC partner responsible for strategic alliances and corporate limited-partner relationships. Her prior experience includes healthcare equity research at Wells Fargo, Leerink Swann and ABN AMRO, consulting at Arthur Andersen, and hospital finance at Massachusetts General Hospital.

Mariam Raad is a software developer on Living Brain’s current published team. The current role title supersedes an older Unity Intern label in the source image alt. The named company-published photograph is preserved without inferring additional qualifications.

Mégane Maillot is a 3D artist on Living Brain’s current public team, contributing to virtual rehabilitation environments. The portrait is published immediately alongside her named card and uses the Megan_V1 filename; its copied Christian alt label is a website metadata error rather than evidence of a second Christian identity.

HCC associate who joined in 2025 following healthcare investment banking at Cain Brothers. He studied finance at Indiana University with a computer-science minor.

Thomas Böhme is a 3D artist on Living Brain’s current public team, supporting its virtual-reality rehabilitation environments. The employer’s exact named card and portrait establish the role.

Till Ikemann joined Living Brain in2019 as technical co-founder and CTO. His game-development training and experience building a games business informed the company’s VR rehabilitation software. The issuer’s2022 press kit documents responsibility for technical development. He is absent from the current team directory; the CTO appointment is retained as historical with no inferred current employment or departure date.

Health Catalyst Capital (HCC) is a New York private-equity manager focused on healthcare information technology and healthcare services. Its legal adviser is Health Catalyst Capital Management LLC, SEC CRD282602/file801-119194; it is distinct from the publicly traded Health Catalyst healthcare-software company. Founded in2015, HCC invests in growth businesses through primary capital and secondary share purchases, supporting virtual care, process automation, data and AI, value-based care and patient engagement. Its official portfolio includes neuroscience and behavioral-health technology such as Click Therapeutics and Holmusk, and healthcare AI/data platforms including Pager Health, Clearsense, Quarvis, Datavant and Insightin. Portfolio listing alone does not establish a financing stage, ticket or currently held ownership. Its current directory publishes six core professionals and seventeen external advisers, whose external career histories are not asserted as current full-time HCC employment. April28,2026 FormADV corroborates the legal manager and six exact private vehicles, including flagship, annex, continuation and CFG-Elevance One partnerships. Regulatory assets, gross fund assets, targets, secondary purchase values and conditional subscriptions are not presented as completed fundraising cash. Direct SEC FormD filings establish a fully sold USD4M Annex FundII offering and USD103,763,908 CFG-Elevance One offering; the other vehicle sizes remain qualified or undisclosed. Its actual Click2021SeriesB participation is recorded separately with no assumed individual ticket or fund allocation. Native authentic logo and named portraits are retained; CFO Paula Semelmacher’s website silhouette is rejected, with no fabricated replacement.

Living Brain GmbH is a Heidelberg neurotechnology company developing virtual-reality software for cognitive rehabilitation. Founded in 2019 by psychologists Barbara Stegmann and Julian Specht, and subsequently joined by technical co-founder Till Ikemann, it combines everyday activities, psychology, gamification and personalised training. Its teora mind software lets patients practise daily tasks in virtual environments and is intended for rehabilitation of cognitive abilities affected by nervous-system diseases. The current legal notice identifies Julian Specht as managing director and Mannheim commercial-register number HRB733845. Its current published team directory names five people; Stegmann and Ikemann are retained as historical founders rather than assumed current executives. The manufacturer labels teora mind as a class IIa medical device; its 2026 instructions identify CE0123 and Basic-UDI-DI PP1076900156. The published TÜV SÜD certificate Q51092750001 is specifically an ISO13485 quality-management-system certificate, valid May9,2025 through October6,2027, and does not itself certify a product marketing authorisation. Its website explicitly distinguishes teora body and teora platform as products without that medical-device certification. No FDA authorisation, drug approval or DiGA reimbursement is established by the reviewed sources. The appointed provisional insolvency administrator’s own August2026 press page confirms the company filed for insolvency in Heidelberg; a later reported opening date requires direct court confirmation. The company announced a completed seven-figure seed capital increase on July11,2022 involving the Companisto investor network and individual business angels Ina Schlie and Dorit Posdorf. The platform reports two closed campaigns with EUR1,491,950 in 2022 and EUR739,132 in 2024; these are exclusively network participation amounts, not verified complete issuer-round totals.

HCC founder and managing partner who leads its investment committee. His healthcare research career includes Credit Suisse, Goldman Sachs and Citi, following technology consulting at Accenture. He studied engineering at Cornell and analytic finance and statistics at Chicago.

Kathryn E. Wengel Director Kathryn E. Wengel has served as a director of the Company since March 25, 2021. Ms. Wengel has served as the Executive Vice President, Chief Technical Operations & Risk Officer of Johnson & Johnson, a leading healthcare company, since January 2023, and as an Executive Committee member and an Executive Officer of Johnson & Johnson since July 2018. Ms. Wengel has significant healthcare, operations, and global business expertise, with more than three decades of experience in leadership positions at Johnson & Johnson in the United States and various locations globally, including as its Worldwide VP and then Executive Vice President, Chief Global Supply Chain Officer from March 2014 through December 2022, and its first Chief Quality Officer from April 2010 until March 2014. Ms. Wengel has served as the Chair of the Board of Directors at the National Association of Manufacturers in the U.S. and is a member of their Executive Committee, as well as a member of the Board of GS1 Global, a nonprofit that develops and maintains global supply chain standards. Ms. Wengel holds a Bachelor of Science in Engineering degree in civil engineering and operations research from Princeton University.

John H. Sampson, MD, PhD, MHSc, MBA Director John H. Sampson has served as a director of the Company since February 9, 2026. Dr. Sampson is the Richard D. Krugman Endowed Chair, Vice Chancellor for Health Affairs, Dean of the University of Colorado Anschutz School of Medicine, and President of CU Medicine. Prior to serving at the University of Colorado, he was Senior Vice Present in the Duke University Health System and led the Duke Health Integrated Practice. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He is a practicing neurosurgeon and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease. Dr. Sampson was born in Canada and holds a Bachelor of Science degree and an MD from the University of Manitoba. He is a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians.

Richelle P. Parham Director, Chairperson of the Compensation and Human Capital Committee Richelle Parham has served as a director of the Company since February 8, 2016 and Chairperson of the Compensation and Human Capital Committee since June 2023. Ms. Parham previously served as President of Global eCommerce and Business Development for Universal Music Group, a music-based entertainment company, a position she has held from June 2021 to June 2025. In October 2019, Ms. Parham became a Managing Director of WestRiver Group, which provides integrated capital solutions to the global innovation economy with investments focused on technology, life sciences, energy, and experiential sectors. She previously served as a General Partner at Camden Partners, a private equity firm, from October 2016 to October 2019. Prior to Camden Partners, Ms. Parham served as Chief Marketing Officer of eBay from November 2010 to March 2015. Ms. Parham was responsible, globally, for developing eBay brand strategy and brand marketing to reach 108+ million active eBay users. Prior to joining eBay, Ms. Parham served as head of Global Marketing Innovation and Initiatives and head of Global Marketing Services at Visa Inc. from 2008 to 2010. Her experience also includes 13 years at Digitas, Inc., a leading marketing agency, where she held a variety of senior leadership roles, including senior vice president and general manager of the agency’s Chicago office. Ms. Parham has served as a Director of Best Buy Co., Inc. since March 2018. She served on the board of directors for e.l.f. Beauty, Inc. from March 2018 to June 2022 and Scripps Network Interactive Inc. from 2012 until March 2018, when Scripps Network Interactive was acquired by Discovery Communications. Ms. Parham holds double Bachelor of Science degrees in business administration and design arts from Drexel University. She became a member of the Drexel University board of trustees in 2014.

Kirsten M. Kliphouse Director Kirsten M. Kliphouse has served as a director of the Company since October 12, 2022. Ms. Kliphouse previously served as the President of Google Cloud Americas, a public cloud vendor that offers a suite of computing services, a position she held from March 2022 to June 2023, where she was responsible for leading and growing the sales, go-to-market, customer engagement, channel, and services organizations. At Google Cloud, she also served as the Global Chair of the Aspiring Leadership Academy and Women@Google Cloud. Prior to her position as President, Ms. Kliphouse served as President of the North American division of Google Cloud from June 2019 to March 2022. Prior to Google Cloud, Ms. Kliphouse was Senior Vice President at Red Hat, Inc., a subsidiary of International Business Machines Corporation, Chief Executive Officer of Yardarm Technologies, a hardware and software solutions company, and founder and Chief Executive Officer of Scaling Ventures, a technology investment and advisory firm. Prior to her position at Yardarm, Ms. Kliphouse spent more than 25 years at Microsoft, Inc., where she was part of the executive leadership team and held numerous executive positions in Enterprise Sales, Original Equipment Manufacturers (OEM), Partner and Channels, and as Corporate Vice President of Customer Support, Success and Professional Services, during which she led more than 10,000-employees globally. Ms. Kliphouse is a recipient of the Founders Award for her superior leadership and contributions to the business. Ms. Kliphouse has served as a director of Global Payments, Inc. since October 2023. Ms. Kliphouse previously served as a director of Dun & Bradstreet Holdings, Inc. from July 2023 to August 2025 and also served as a director of Vimeo, Inc. from June 2025 until the Company’s acquisition in November 2025. Ms. Kliphouse holds a degree in Computer Information Sciences and Business from Muhlenberg College.

Jeffrey A. Davis Director, Chair of the Audit Committee Jeffrey A. Davis has served as a director of the Company since December 1, 2019, and Chairman of the Audit Committee since June 2023. Mr. Davis previously served as the Chief Financial Officer of Dollar Tree, Inc. from October 2022 through March 2025. Prior to his time at Dollar Tree, Inc., Mr. Davis served as Chief Financial Officer of Qurate Retail Group, a leading retailer and media conglomerate comprised of eight retail brands including QVC, HSN and Zulily, from October 2018 through August 2022. Prior to Qurate Retail Group, Mr. Davis served as Chief Financial Officer of J. C. Penney Company Inc., a retail company, from July 2017 until September 2018. Prior to joining J. C. Penney, Mr. Davis served as Chief Financial Officer of Darden Restaurants Inc., a restaurant operator, from July 2015 until March 2016 and Chief Financial Officer of the Walmart U.S. segment of Walmart Inc. from January 2014 to May 2015, and in various other positions of increasing responsibility at Walmart U.S. from 2006 to 2013. Mr. Davis previously served on the Board and Audit Committee of Massmart Holdings Limited (MSM: Johannesburg Stock Exchange), a South African retailer, from 2011 to 2014, on the Board of Visitors for the Wake Forest University School of Business from 2015 to 2017, and on the Board of Visitors for the Joseph M. Katz Graduate School of Business at the University of Pittsburgh from 2010 to 2016. Mr. Davis’ experience also includes nine years in senior executive roles at Lakeland Tours LLC and McKesson Corporation. Mr. Davis holds a bachelor’s degree in accounting from the Pennsylvania State University and a master’s degree in business administration from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Mr. Davis is a certified public accountant (inactive) and has received a CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute as part of the National Association of Corporate Directors’ Cyber-Risk Oversight Program.

Victor Bulto Director Victor Bulto has served as a director of the Company since December 1, 2025. Mr. Bulto is President of Novartis US and a member of the Novartis Executive Committee since April 2022. In this role, he leads a bold strategy to reimagine medicine and improve patient care in the world’s largest healthcare market. Mr. Bulto has spearheaded commercial transformation and championed the integration of technology, advanced analytics, real-world evidence and early detection strategies to accelerate access and improve patient outcomes. With more than two decades at Novartis, he has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr. Bulto holds a Master’s in Health Economics and Pharmacoeconomics and a Postgraduate Degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. He earned his MBA from ESADE and completed the Advanced Management Program at Harvard Business School. He also holds a Master’s in Chemical Engineering and a Bachelor of Science in Chemistry from Institut Químic de Sarrià in Spain.

Pete Wilder is listed by Oxford Science Enterprises as Head of Property & Operations. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Peter Weston-Smith is listed by Oxford Science Enterprises as Senior Associate, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jon Wall is listed by Oxford Science Enterprises as Portfolio Talent Lead, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Katherine Ward is listed by Oxford Science Enterprises as Operating Partner, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Kerrii B. Anderson Director Kerrii B. Anderson has served as a director of the Company since May 17, 2006. Ms. Anderson is the former Chief Executive Officer, President and Chief Financial Officer of Wendy’s International. Prior to joining Wendy’s in 2000, she was senior vice president and chief financial officer for 14 years for M/I Homes, Inc., a public company that builds single-family homes. Ms. Anderson has served as a director of Abercrombie & Fitch Co. since February 2018, The Sherwin-Williams Company since April 2019, and Worthington Industries, Inc. since September 2010. She was previously a director of the board of Chiquita Brands International from 2009 to 2012, and was chairwoman of the board from 2012 until the company’s acquisition in 2015. She was also a member of the board of P.F. Chang’s China Bistro from 2009 to 2012. Ms. Anderson also serves on the boards of the following non-profit entities: The Columbus Foundation and Elon University Board of Trustees. Ms. Anderson has received a CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute as part of the National Association of Corporate Directors’ Cyber-Risk Oversight Program.

Sami Walter is listed by Oxford Science Enterprises as Senior Associate, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Wallace Wallace is listed by Oxford Science Enterprises as Senior Associate, Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Andrew Straiton is listed by Oxford Science Enterprises as Senior Associate, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Andy Penfold is listed by Oxford Science Enterprises as Content Lead. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Bernard Taylor is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

George Todd is listed by Oxford Science Enterprises as Principal, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Heather Roxborough is listed by Oxford Science Enterprises as Senior Partner, Head of HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jack Strudley is listed by Oxford Science Enterprises as Head of Finance. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Joel Schoppig is listed by Oxford Science Enterprises as Partner, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

John Roberts is listed by Oxford Science Enterprises as Senior Compliance Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Katharina Ramshorn is listed by Oxford Science Enterprises as Senior Associate, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Katya Smirnyagina is listed by Oxford Science Enterprises as Advisor, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Molly Stevens is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Richard Oakley is listed by Oxford Science Enterprises as Principal, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Satoko Robertson is listed by Oxford Science Enterprises as Executive Assistant & Legal Secretary. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sive Ozer is listed by Oxford Science Enterprises as Head of Legal, Investing. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Alicia Mederick is listed by Oxford Science Enterprises as Team Co-ordinator. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Gaëlle Newton is listed by Oxford Science Enterprises as Events Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jeff Moore is listed by Oxford Science Enterprises as Senior Partner, Head of Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established. Jeff Moore, also published as Jeffrey B. Moore and legally Jeffrey Bernard Moore, formerly led MP Healthcare Venture Management as President. Oxford Science Enterprises’ September 29, 2026 announcement confirms his move to Senior Partner and Head of Life Sciences and describes MPH as his preceding position. He led early-stage biotechnology investments from academic discovery to exit, including Covagen, F-star, Korro Bio, miRagen, Genocea and Trimtech. His current Oxford affiliation is preserved; historical MPH biographies must not be treated as proof of a current MPH presidency. He holds a DPhil from Oxford, an MBA from MIT and a biology degree from the University of New Brunswick; his career includes infectious-disease postdoctoral work at Harvard Medical School, Research Corporation Technologies, Millennium and Scriptgen. The exact final day of MPH employment is not established.

Matt Myers is listed by Oxford Science Enterprises as Senior Associate, Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Matt Nicholls is listed by Oxford Science Enterprises as Advisor. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Céline Leclere is listed by Oxford Science Enterprises as Executive Assistant, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Daoud Khan is listed by Oxford Science Enterprises as Finance Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Emily Matthews is listed by Oxford Science Enterprises as Responsible Investment & ESG Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jeanette Lovis is listed by Oxford Science Enterprises as Executive Assistant. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Lauren Laing is listed by Oxford Science Enterprises as Principal, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Matthew Hunt is listed by Oxford Science Enterprises as Legal Counsel. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Oliver Mahony is listed by Oxford Science Enterprises as Partner, Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Rachel McKee is listed by Oxford Science Enterprises as Senior People Advisor. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Snigdha Lal is listed by Oxford Science Enterprises as Associate, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Tatiana Lobanov-Rostovsky is listed by Oxford Science Enterprises as Associate, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jon Hepple is listed by Oxford Science Enterprises as Advisor, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Julia Wang Executive Vice President and Chief Financial Officer Julia Wang has served as Executive Vice President and Chief Financial Officer of Labcorp since December 2024. Prior to joining Labcorp, Julia served as CFO of BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) since 2021, which she joined in 2020 as Senior Vice President, Enterprise Optimization and Deputy CFO. While at BeiGene, she was instrumental in driving business transformations through accelerating growth, nurturing innovation and cultivating a culture of sustainable operating efficiencies. Julia served as Senior Vice President, Global Business Finance and Corporate Planning at Alexion Pharmaceuticals prior to BeiGene. Before Alexion, she held leadership positions at Quest Diagnostics (NYSE: DGX), including Vice President of Finance, U.S. Regional Business and Enterprise Commercial, and Vice President of Finance, Value Creation. Julia held senior leadership roles at Johnson & Johnson (NYSE: JNJ) as CFO of various operating businesses in medical device and pharmaceuticals earlier in her career. Previously, she led finance initiatives at PepsiCo. Julia earned her MBA from Fuqua School of Business at Duke University and her BA in British Language and Literature from Shandong Normal University.

Richard Hobbs is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Marlou Hanselmann is listed by Oxford Science Enterprises as Communications & Digital Marketing Executive. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sam Harman is listed by Oxford Science Enterprises as Partner, Head of Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sam Harris is listed by Oxford Science Enterprises as Senior Associate, Capital Formation & Investor Relations. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Alex Hammacher is listed by Oxford Science Enterprises as Head of Strategic Operations & Corporate Finance. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Andre Crawford-Brunt is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Athene Blakeman is listed by Oxford Science Enterprises as General Counsel. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Benny Axt is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Charo Bajo is listed by Oxford Science Enterprises as Data & Projects Manager. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Chris Chambers is listed by Oxford Science Enterprises as Non-Executive Chairman. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Christopher Ashton is listed by Oxford Science Enterprises as Advisor, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Claire Brown is listed by Oxford Science Enterprises as Partner, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Clare Gumbley is listed by Oxford Science Enterprises as Portfolio Talent Lead, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Harry Clifford is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Iwona Dombek-Wieczorek is listed by Oxford Science Enterprises as Finance Officer. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

James Finlayson is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Liliane Chamas is listed by Oxford Science Enterprises as Principal, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Lilly Bussmann is listed by Oxford Science Enterprises as Partner. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Lisa Bedwell is listed by Oxford Science Enterprises as Head of Marketing. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Mark Chadwick is listed by Oxford Science Enterprises as Scientist-in-Residence, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Martin Fiennes is listed by Oxford Science Enterprises as Advisor, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Nick Dixon-Clegg is listed by Oxford Science Enterprises as Partner, Head of Independent Investments. The published affiliation belongs to the Independent team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Nico Babaian is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Paul Galluzzo is listed by Oxford Science Enterprises as Entrepreneur-in-Residence, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Peter Donnelly is listed by Oxford Science Enterprises as Non-Executive Director. The published affiliation belongs to the Board team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Polly Elvin is listed by Oxford Science Enterprises as Partner, Capital Formation & Investor Relations. The published affiliation belongs to the Central team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sally Dewhurst is listed by Oxford Science Enterprises as Principal, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Sanne De Jongh is listed by Oxford Science Enterprises as Partner, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Suzanne Algie is listed by Oxford Science Enterprises as Team Co-Ordinator, Life Sciences. The published affiliation belongs to the Life Sciences team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Tony Besse is listed by Oxford Science Enterprises as Principal, HealthTech. The published affiliation belongs to the HealthTech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

William Goodlad is listed by Oxford Science Enterprises as Advisor, Deep Tech. The published affiliation belongs to the Deep Tech team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Antonia Jenkinson is listed by Oxford Science Enterprises as Chief Financial Officer. The published affiliation belongs to the Executive team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Ed Bussey is listed by Oxford Science Enterprises as Chief Executive Officer. The published affiliation belongs to the Executive team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Jack Edmondson is listed by Oxford Science Enterprises as Chief Investment Officer. The published affiliation belongs to the Executive team or advisory category. Current directory reviewed October7,2026; exact appointment date is not established.

Bryan Vaughn Executive Vice President and President, Diagnostics Bryan Vaughn is Executive Vice President & President, Diagnostics at Labcorp, where he oversees the company’s operating divisions and commercial growth strategy. Bryan joined Labcorp in 2009, and since that time, has held multiple leadership roles. Most recently, he served as Senior Vice President, Health Systems & Mid-America Division, leading diagnostic operations across 19 states and managing enterprise partnerships with health systems and national accounts. He has led Labcorp’s health system growth strategy since 2017. Previously, he served as Vice President of Finance for Labcorp’s Atlantic Division, and earlier, Director of Women’s Health Segment Marketing and Director of Strategic Planning and Corporate Development, where he helped shape business strategy, drive product development and expand Labcorp’s market presence. Before joining Labcorp, Bryan worked in healthcare investment banking at Raymond James, a leading financial services firm, and in health advocacy at Cigna, a global health services company. Bryan holds a Bachelor of Arts in economics from Vanderbilt University and a Master of Business Administration with a concentration in health sector management from Duke University’s Fuqua School of Business.

Amy Summy EVP, Chief Marketing Officer and Consumer Health Lead Amy Summy has served as EVP, Chief Marketing Officer and Consumer Health Lead at Labcorp since March 2020. She is responsible for global marketing including brand, go-to-market strategy, omnichannel marketing, ecommerce, commercialization, product management, and communications. She also leads the company’s consumer health business under the brands Labcorp OnDemand and Ovia Health. Amy is a member of Labcorp’s Environmental, Social and Governance (ESG) and Venture Fund Steering Committees, and serves as the Executive Sponsor for EnABLE (an Employee Resource Group for people with disabilities). Prior to Labcorp, Amy was a partner with Ernst & Young (EY), where she led EY Digital’s Marketing and Insights Practice from 2018 to 2020. She joined EY from TE Connectivity a global manufacturer of connector and sensor technologies, where she was SVP and CMO and a member of TE’s Operating Committee. At TE, she led the transformation of the brand and customer facing functions, embedding digital capabilities and data in the marketing, product introduction, sales and service processes. She developed and launched TE’s ecommerce business, aimed at small- and mid-size customers in North America, Europe and China. Prior to TE, Amy held executive roles at global digital consultancy Sapient during the company’s growth from 300 employees to over 10,000 employees and $1B in revenue. As Senior Vice President and Managing Director, she led the New York, West Coast and financial services businesses. Amy began her career at Dun & Bradstreet. Amy serves as a board member of the San Diego Natural History Museum, board observer of venture-backed NowDx, and a member of the Corporate Council of the Children’s Hospital of Philadelphia. She holds a Bachelor of Business Administration in finance from Kent State University and a Master of Business Administration in finance and international business from the Stern School of Business at New York University.

Bola Oyegunwa, Ph.D. EVP, Chief Information and Technology Officer Bola Oyegunwa, Ph.D., has served as Labcorp’s Executive Vice President and Chief Information and Technology Officer since November 2024. Since joining Labcorp in 2019 as Vice President of Decentralized Clinical Trials Technology, Bola has pioneered advancements in remote clinical trials technology, significantly enhancing patient accessibility to trials. He went on to serve as Chief Information Officer for Labcorp’s Drug Development segment, where he led digital transformation, expanded robotic process automation, and developed technology solutions for investigators and sponsors alike. In his most recent role as Senior Vice President of Enterprise Systems, Data & Technology, Bola directed essential functions such as laboratory systems, corporate systems, robotics, and data engineering. His leadership delivered transformative technology solutions across Labcorp’s Diagnostics and Biopharma Laboratory Services segments. Before Labcorp, Bola held leadership positions as Global Head of Virtual Trials Technology and Director of Corporate Strategy at IQVIA, and Global Head of Corporate and Digital Strategy at Cenduit. He has also advised private equity and venture capital firms and served as a board advisor for Headlands Research, a KKR portfolio company. Bola holds a Doctorate in Microbiology and Immunology, a Master’s in Microbial Biotechnology, and an MBA from North Carolina State University.

Anita Graham EVP and Chief Human Resources Officer Anita Graham has served as Executive Vice President and Chief Human Resources Officer since 2023. Before joining Labcorp, Anita served as Executive Vice President, Chief Human Resources Officer and Public Affairs at VF Corporation, one of the world’s largest lifestyle-focused footwear and apparel companies. In addition to leading the human resources function through major business transformations, she oversaw the company’s public affairs initiatives, including corporate communications, government relations, community relations and the VF Foundation. Prior to VF, Anita served as Senior Vice President, Chief Human Resources and Administration Officer at ADT Corporation, where she led the human resources, environment, health and safety, and corporate communications functions. Previously, she was the Executive Vice President, Chief Administrative Officer at Shire plc, a global biopharmaceutical company that is now part of Takeda Pharmaceuticals. Anita currently holds board-level roles in several professional organizations including the Human Resources Policy Association, the Center on Executive Compensation and the Center on Executive Succession. She is also a member of the national board for The Trust for Public Lands. She holds a Bachelor of Science in industrial and labor relations from Cornell University and a Master of Business Administration in finance from the Stern School of Business at New York University.

Jon Meltzer, Ph.D. Executive Vice President, Chief Operations Officer Jon Meltzer, Ph.D., is Executive Vice President, Chief Operations Officer at Labcorp, where he oversees the company’s diagnostics lab operations, global supply chain, and enterprise strategy. Jon joined Labcorp in 2006 and has held leadership roles of increasing responsibility. Most recently, he served as Senior Vice President of Laboratory Operations, leading operations across more than 30 laboratory locations and oversight of the P&Ls for the Esoteric business units. Previously, he held a series of senior leadership roles, including Senior Vice President of Strategy, Senior Vice President of Esoteric Businesses, Senior Vice President of Specialty Oncology, and Vice President of Corporate Development, in which role he managed licensing, partnerships, mergers and acquisitions, and led the Labcorp Venture Fund. Jon also played a pivotal role in Labcorp’s pandemic response, directing efforts that delivered more than 70 million COVID-19 PCR tests and supported next-generation sequencing surveillance for the U.S. Centers for Disease Control and Prevention. Before joining Labcorp, Jon worked in venture capital, the Duke Office of Licensing and Ventures, and the North Carolina Department of the State Treasurer. Earlier in his career, he served as a Technology Commercialization Officer at the National Research Council of Canada and co-founded a company manufacturing molecular reagents for biomedical research. Jon holds his Bachelor of Science and a Doctorate in Anatomy from the University of Manitoba and a Master of Business Administration from Duke University’s Fuqua School of Business.

Kathryn W. Kyle Executive Vice President, Chief Legal Officer and Corporate Secretary Kathryn Kyle has served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Labcorp since January 2026. Kathryn joined Labcorp in 2003 in the litigation group and has advanced through broader leadership roles in the law department since that time, becoming General Counsel in 2016. Under her leadership, Labcorp has successfully managed major litigation matters and reorganized various legal functions, including intellectual property areas and professional liability claims. Kathryn also successfully introduced legal support technology into core legal functions and provided critical strategic support to the enterprise during crisis events, including the Covid-19 pandemic. Prior to joining Labcorp, Kathryn was a Senior Corporate attorney with Polaroid Corporation, where she was primarily responsible for employment and labor issues. She previously served as a litigation associate at a western Massachusetts law firm. Kathryn received her Bachelor’s degree from Smith College and her Juris Doctorate from Emory University School of Law.

Adam Schechter Chairman, President, and Chief Executive Officer Adam Schechter became Chief Executive Officer of Labcorp in 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director after serving as a director of the company since 2013. Before joining Labcorp, Mr. Schechter held a variety of senior leadership positions at Merck & Co., Inc. He was Executive Vice President and President of Merck’s Global Human Health Division from 2010 to 2018 leading the company’s worldwide pharmaceutical and vaccine businesses. In this role, he was also a member of Merck’s executive committee. Prior to becoming President of Merck’s Global Human Health Division, Mr. Schechter served as President of Merck’s global pharmaceutical business from 2007 to 2010. His extensive experience at Merck also included global and U.S.-focused leadership roles spanning sales, marketing and managed markets, as well as business and product development. Mr. Schechter has been a Board Member for DaVita Inc. since 2022, and he serves on the Board for Water.org. He also serves as the American Clinical Laboratory Association (ACLA) Board Vice-Chair, and a member of the Corporate Advisory Council for the National Alliance for Hispanic Health. In 2025, Mr. Schechter joined the Board of Project HOPE, a leading global health and humanitarian organization. Previously, he served on the Boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company. Mr. Schechter holds a Bachelor of Science degree in biology and an honorary Doctorate of Humane Letters degree from La Salle University in Philadelphia, Pennsylvania.

Bjoern von Siemens is a Caresyntax cofounder and investor. PatrickPfeffer names him among the collaborators behind the2025 ACPHealthtech launch; ACP’s own announcement separately names the vonSiemensfamily as an anchor investor. This is a qualified investment affiliation, not proof that Bjoern personally supplied a particular LP commitment or held an unspecified operatingjob. Caresyntax’s July2025 ownannouncement confirms his continuing board and capital-market/corporate-development work after MattKrueger became CEO.

Emma Hague is a healthcare entrepreneur and investor. A2024 Carmo Companies speaker biography identifies her as a private wealth holder and general partner at ACPHealthtech. It describes founding and selling a human-data analytics business to IQVIA, and later direct and family-office healthcare investing, advising and board work. The affiliation is retained with its dated2024 evidence; current2026 tenure is unconfirmed. Her genuine portrait is the original image in that organizer biography.

Helmut C. Nanz is named in PatrickPfeffer’s own2025 ACPHealthtech launch announcement as an investment collaborator; his own reply confirms involvement in that journey. The available primary evidence does not specify a current employee title, partner legal appointment or individual LP amount. This profile records the named affiliation with those limits and does not merge him with unrelated family members or infer a private check.

ACP Healthtech Management GmbH is a Frankfurt-based German alternative investment fund manager, operating as ACP Healthtech / Aescuvest Capital Partners. The active legal entity is registered as HRB136350 and LEI391200HDEFESFM5GE394; its official legal registration dates to2024. It manages the closed-ended venture fund Aescuvest Capital Partners Healthtech Fund I GmbH & Co.KG, investing equity and equity-like capital primarily in European healthcare technology companies at regulatory and commercial inflection points. Its mandate covers AI diagnostics, medical software, devices and robotics. Patrick Pfeffer is the published managing partner, Olivier Gracia identifies himself as CFO and general partner, and Christoph Bartoschek is the issuer-quoted investment principal. Published launch collaborators and historical partners are distinguished from current employee appointments. Fund I’s first close is confirmed by the founder, but the capital amount and exact closing day are undisclosed. ACP is a distinct legal manager from Aescuvest GmbH’s individual-SPV investment platform; historical platform investments are not automatically migrated to the fund or duplicated under both managers. Its current site anonymizes selected portfolio descriptions; exact issuers are linked only when named primary evidence confirms the relationship.

Camilo Rico is an Accelmed principal with healthcare consulting, investing and investment-banking experience. His earlier employers include SFW Capital Partners, Citi’s healthcare investment-banking group and L.E.K. Consulting. He earned business and international-studies graduate degrees at the University of Pennsylvania and an undergraduate degree at Boston College.

Ilan Ben-Oren is Accelmed’s chief technology officer. He brings medical-technology research, development and management experience, including earlier technology leadership at Exalenz Bioscience. His career covers medical-device product development and clinical technologies.

Susan Alpert is Accelmed’s chief regulatory officer. Her earlier work includes senior regulatory leadership at Medtronic and C.R. Bard and FDA device-evaluation leadership. Her qualifications include medical microbiology and medicine, with experience in pediatric infectious disease and clinical research.

Guy Ohad is Accelmed’s chief medical officer and a radiologist with medical-device and technology experience. He previously led POP Medical Solutions, later FEMSelect, and held clinical and business-development responsibilities at Orex. He earned his medical degree at Tel Aviv University.

Irit Yaniv is an Accelmed venture partner whose published biography specifically describes responsibility for the historic Accelmed Ventures portfolio. She co-founded Digma Medical and NitiNotes and is a co-founder and chair of Almeda Ventures. She is a physician with an MBA from Tel Aviv University.

Daniel Cohen is an Accelmed venture partner, formally joining in2022 after more than a decade of work with the firm. His healthcare investment work includes an independent investment consulting business and leadership of Fosun Pharma in Israel. He studied applied mathematics and computer engineering and earned an MBA at ESSEC.

Stephen Rubin is an Accelmed general partner. Previously he co-led Proskauer’s private-equity practice, advising on acquisitions, private-equity and debt offerings and financing transactions. He studied law at Columbia and earned an undergraduate degree at Cornell.

Uri Geiger founded Accelmed and is its managing partner. He previously built Exalenz Bioscience and GalayOr Networks and co-founded the Dragon Variation Fund. His experience spans healthcare company leadership, investing and capital markets; he earned a doctorate at Columbia University and previously taught private equity and venture capital at Tel Aviv University.

Burnt Island Ventures is a venture capital firm focused on technology and infrastructure for the water sector. It backs founders developing treatment and filtration systems, water reuse and desalination, smart metering, flood resilience, utility software, AI and digital tools for managing water infrastructure. Its seed strategy invests across the water value chain, while its growth strategy backs companies that have established commercial traction and are scaling. The firm combines water-industry operating experience, technical diligence and specialist networks with support for hiring, fundraising, commercialization and board-level decisions. Founded in 2020, it works with entrepreneurs globally and connects them with industrial partners and potential acquirers.

MUUS Climate Partners is the climate-focused investment arm affiliated with MUUS & Company, the private investment business established by Michael Sonnenfeldt. It backs early-stage and growing companies at the intersection of advanced technology and decarbonization, focusing on solutions approaching commercial deployment. Its climate portfolio includes industrial water treatment, engineered materials, energy forecasting and software, clean energy generation and storage, electrification, fusion, advanced manufacturing and resource efficiency. The team combines investment execution, climate expertise and operating support to help companies scale. MUUS’s current climate practice also invests across the capital stack; the climate arm and parent company remain distinct published affiliations. Its dedicated climate investment activity began in 2016.

Published name: Jeff Weiss. This profile refers to Clean Energy Ventures. Existing same-name identities and their affiliations are preserved.

Published name: Matt Cohen. This profile refers to Clean Energy Ventures. Existing same-name identities and their affiliations are preserved.

OCCTE is a French mission-driven portfolio-management company founded in 2021 to finance the energy transition and strategic, sustainable sectors. Its active legal entity is OCCTE SAS, SIREN900650136, created June10,2021, with AMF authorization GP202220 granted in August2022. Based in Toulouse with a team serving Toulouse and Montpellier, it developed from AREC Occitanie’s investment activities. Its climate-infrastructure investments cover renewable electricity, storage and flexibility, charging infrastructure, renewable heat, green hydrogen, floating offshore wind and industrial decarbonization. Its first vehicle, FPCI OCCTE OCCIGEN, completed a EUR25M first close on November25,2022; its current published fund size is EUR104M, with no stated final-closing date. The separately announced EUR75M EIF commitment is a subscriber commitment, rather than a new manager financing or an additional fund. OCCIDEV Impacts targets sustainable growth and late-stage companies in health, digital technology, industry, energy, food and environmental solutions; its EUR50M goal is a target with no demonstrated closing amount. Its publicly announced investments include Dev’EnR, Orsana and renewable-energy developer Eléments. Since February2023, OCCTE has also provided operational management to the legally separate ARIS Occitanie investment company under a service contract. This does not make OCCTE the named ARIS/Cilcare shareholder. Groupe Magellim announced a minority investment in OCCTE in May2024, subsequently confirmed in the group’s own corporate description; no undisclosed transaction value is inferred.

Anne-Laure Beuscart is an investment director at OCCTE with experience financing renewable-energy and infrastructure projects. Her prior work includes renewable-energy development at MIDI 2i and financing energy, social-infrastructure and telecom projects at Natixis Global Infrastructure & Projects.

Audrey Laffaille is OCCTE’s head of ESG, as named in its current public team directory. A detailed professional biography is not published on that directory.

Emmanuelle Ostiari is an investment director at OCCTE with a background in sustainable-development research, ESG and private-equity investing. Her published biography identifies prior private-equity investment work at Mirova and low-carbon and green-technology research at Kepler.

Florence Lambert is president and chief executive officer of Genvia, the solid-oxide hydrogen-electrolysis technology company, and previously led CEA-Liten. OCCTE announced her as chair of its consultative committee in December 2022; continuing committee tenure is not separately verified.

Jérôme Lavinaud is an investment director at OCCTE specializing in renewable energy. He previously led energy-transition investing at Sofilaro Gestion and helped establish Crédit Agricole Languedoc’s new-energy investment activity and Calen in 2010.

Julien Gomis is an investment director at OCCTE with experience in industrial private equity, corporate financing and financial audit. His published biography describes aerospace investing, Bpifrance financing work in Occitanie and audit and transaction-services assignments.

Marine Hugot is an investment analyst at OCCTE, as named in its current public team directory. A detailed biography is not published on that directory.

Romain Arette-Hourquet is an investment manager at OCCTE. Trained as an engineer at École des Mines de Paris, he previously worked at Stoa Infra & Energy and developed and financed renewable-heat and energy-efficiency projects at Kyotherm.

aws Fondsmanagement GmbH is the Vienna-based investment manager operating the public aws Gründungsfonds brand. It co-invests with private investors in high-growth Austrian technology startups from seed through Series A and later financing, supporting portfolio companies with financing, strategy and commercialization. The manager is owned by Austria Wirtschaftsservice, the Austrian federal promotional bank, and is registered as an alternative investment fund manager. Its published strategy spans technology companies including AI, software, deep technology and healthcare. It manages the original aws Gründerfonds and aws Gründungsfonds II, which are separate investment vehicles with different investment periods.

IGO Innovation GmbH is the Innsbruck-based startup investment arm of the Austrian IGO Industries group. It acquires and manages stakes in innovative businesses and supplies management and advisory support. Its investments include high-resolution 3D printing company UpNano and life-sciences and high-technology investment company ILUM Tec; the group also publishes a fintech investment in Blue Code. IGO Innovation is a separate legal company from IGO Industries and from ILUM Tec. Its investment activity combines equity capital with the industrial group’s experience in technology businesses and company development.

ILUM Tec GmbH is a Vienna-based investment company backing young Central European life-science and high-technology businesses, with a particular focus on regenerative medicine. It provides seed and follow-on capital, seeks substantial minority stakes and helps companies with financial planning, legal matters, quality and regulatory work, business processes and US commercialization. Its published holdings include AURIMOD’s auricular vagus nerve stimulation technology, Regenera’s spinal-cord-injury regeneration research, ImageBiopsy Lab’s AI imaging software, vascular prostheses, regenerative medical textiles and microfabrication companies. ILUM Tec combines long-term growth financing with potential exits, acquisitions and IPOs rather than publishing a fixed fund vintage.

IGO Innovation managing director since 2023, also known as Axel Melchior, as verified in his issuer-published Porr biography.

Marketing and communications professional supporting investor relations since December 2024.

Supports fund management in organizational matters, reporting and controlling; her own biography dates joining to 2015.

Fund and portfolio professional with prior risk control, fund controlling and auditing experience.

Investment professional with auditing, banking and M&A experience, and accounting and finance studies at WU Vienna.

IGO group executive named as CEO of IGO Innovation in UpNano’s issuer financing announcement.

Joined the own published team in 2026 after startup operations and community-management work in Graz.

Investment professional with corporate innovation experience at weXelerate and strategy and innovation studies at Maastricht University.

Investment professional with prior PwC Deals Advisory experience; the own biography dates his managing-director appointment to December 2023.

Corporate finance, banking and restructuring executive responsible for fund management since 2019.

Venture capital and biotechnology executive. His own biography describes EUCODIS Bioscience leadership and deep-tech investment experience at ARAX Capital Partners.

Former founder of FRYNX and investment manager at Peak Pride, with strategy and innovation studies at WU Vienna.

Corporate finance professional with transaction and restructuring advisory experience.

Glenn Micallef is Commissioner for Intergenerational Fairness, Youth, Culture and Sport in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees intergenerational fairness, youth, culture and sport. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Apostolos Tzitzikostas is Commissioner for Sustainable Transport and Tourism in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees sustainable transport and tourism. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Christophe Hansen is Commissioner for Agriculture and Food in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees agriculture and food policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Michael McGrath is Commissioner for Democracy, Justice, the Rule of Law and Consumer Protection in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees democracy, justice, the rule of law and consumer protection. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Ekaterina Zaharieva is Commissioner for Startups, Research and Innovation in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees startups, research and innovation, including public support for scientific and technological development. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Dan Jørgensen is Commissioner for Energy and Housing in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees energy and housing policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Piotr Serafin is Commissioner for Budget, Anti-Fraud and Public Administration in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees the EU budget, anti-fraud measures and public administration; the EU budget is a public appropriation framework, not a private LP fund close. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Jessika Roswall is Commissioner for Environment, Water Resilience and a Competitive Circular Economy in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees environment policy, water resilience and circular-economy competitiveness. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Hadja Lahbib is Commissioner for Equality Preparedness and Crisis Management in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees equality, preparedness and crisis management. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Magnus Brunner is Commissioner for Internal Affairs and Migration in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees internal affairs and migration. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Maria Luís Albuquerque is Commissioner for Financial Services and the Savings and Investments Union in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees financial services and the Savings and InvestmentsUnion portfolio. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Costas Kadis is Commissioner for Fisheries and Oceans in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees fisheries and oceans policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Jozef Síkela is Commissioner for International Partnerships in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees international partnerships and development cooperation. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Andrius Kubilius is Commissioner for Defence and Space in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees defence and space, including the industrial and technological capabilities needed for European security. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Marta Kos is Commissioner for Enlargement in the European Commission’s current2024–2029 College, which entered office on1December2024. She oversees EU enlargement and the accession process. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Wopke Hoekstra is Commissioner for Climate, Net Zero and Clean Growth in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees climate policy, net-zero transition and clean growth. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Dubravka Šuica is Commissioner for Mediterranean in the European Commission’s current2024–2029 College, which entered office on1December2024. She leads the Mediterranean portfolio and regional partnership responsibilities. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Olivér Várhelyi is Commissioner for Health and Animal Welfare in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees health and animal-welfare policy, including the public-health and regulatory environment in which biotechnology and medical innovation operate. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Valdis Dombrovskis is Commissioner for Economy and Productivity Implementation and Simplification in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees economic policy, productivity, implementation and simplification of EU rules. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Maroš Šefčovič is Commissioner for Trade and Economic Security Interinstitutional Relations and Transparency in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees trade and economic security and the Commission’s interinstitutional relations and transparency responsibilities. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Raffaele Fitto is Executive Vice-President for Cohesion and Reforms in the European Commission’s current2024–2029 College, which entered office on1December2024. He oversees cohesion and reforms, including regional development and reducing economic and territorial disparities. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Roxana Mînzatu is Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness in the European Commission’s current2024–2029 College, which entered office on1December2024. She coordinates social rights, skills, quality employment and preparedness, including workforce skills and education policy. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Kaja Kallas is High Representative for Foreign Affairs and Security Policy Vice-President in the European Commission’s current2024–2029 College, which entered office on1December2024. She leads EU foreign and security policy and contributes as a Commission Vice-President; this diplomatic role is distinct from an individual company investment. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Stéphane Séjourné is Executive Vice-President for Prosperity and Industrial Strategy in the European Commission’s current2024–2029 College, which entered office on1December2024. He coordinates industrial strategy, the single market, SME competitiveness and investment in strategic technologies, including clean manufacturing and critical raw materials. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Henna Virkkunen is Executive Vice-President for Tech Sovereignty, Security and Democracy in the European Commission’s current2024–2029 College, which entered office on1December2024. Her portfolio includes AI innovation, digital and frontier technologies, high-performance computing, cloud infrastructure, quantum technologies and enforcement of digital-market and online-platform rules. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Teresa Ribera is Executive Vice-President for Clean, Just and Competitive Transition in the European Commission’s current2024–2029 College, which entered office on1December2024. She coordinates the green transition, industrial decarbonisation and clean-technology investment, and oversees competition policy, state aid, merger control and DigitalMarketsAct enforcement. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Ursula von der Leyen is President of the European Commission in the European Commission’s current2024–2029 College, which entered office on1December2024. She leads the Commission and its political priorities, having first become Commission President in2019 and secured a second mandate inJuly2024. Her own October2026 agenda confirms continuing service. This is a public institutional leadership appointment; no personal investment check is implied. Current official role and portfolio reviewed7October2026.

Catherine Juillard is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Christine Defert is a Dassault Systèmes employee-representative director appointed by the CFDT union. She has been an executive assistant in its Industries organization since2007 after office-management and assistant roles at French startups. She served on the French works council and as its deputy board representative2017–2024 and on the European committee2020–2024. Her own profile also identifies CFDT metallurgy-union executive membership and labor-court judicial service since2023.

Delphine Da Maia-Levy is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Isabelle Fuzellier is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Julien Mouret is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Marie Dumas is named in Dassault Systèmes’ current official investor-contact directory. The directory explicitly identifies her as Investor Relations Director. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Michele de Souza is named in Dassault Systèmes’ current official investor-contact directory. The directory establishes an investor-relations contact affiliation, without publishing a more specific position, career history or education. No authentic original portrait was verified in the retrieved primary directory. The affiliation is not an investment-partner role or a personal company check.

Anne-Laure Chevalier is a Dassault Systèmes employee-representative director appointed by the CFE-CGC union. She has led legal development and organization since2018, following legal special projects and deployments from2010 and progressively senior contract/legal roles1992–2010. She joined the company’s documentation-translation team in1990. She has a postgraduate English and American business-law qualification from Paris I Panthéon-Sorbonne.

Donatella Sciuto is an independent Dassault Systèmes director, rector of Politecnico di Milano and professor of information-processing systems. She studied electronic engineering, earned an electrical/computer-engineering PhD from the University of Colorado Boulder and a Bocconi MBA. Her own biography reports more than400 scientific articles and four international patents, IEEE electronic-design-automation leadership, Academia Europaea membership and recognition for women’s AI leadership. She promotes STEM inclusion and holds additional Italian corporate and institutional governance roles.

Eric Trappier is a Dassault Systèmes director, GIMD chairman since2025 and Dassault Aviation chairman and CEO since2013. An engineer educated at Sud Telecom, he joined Dassault Aviation in1984 and progressed through technical, sales, regional and international leadership positions. His own current biography identifies additional Dassault-group boards and aerospace/industrial association roles. Dassault Aviation and GIMD remain distinct from the software parent; his group offices do not imply personal Click cash participation.

Marie-Hélène Habert-Dassault is a Dassault Systèmes director and leads communication and patronage at Groupe Industriel Marcel Dassault. She joined GIMD in1991 after working in London media planning at DDB Publicité. She has postgraduate corporate-law and taxation studies from Assas and a strategy/marketing master’s from Sciences Po. Her own current biography identifies governance roles at GIMD, Dassault Aviation, Serge Dassault Foundation, Biomérieux and research foundations. Corporate and family affiliations do not prove personal investments.

Nathalie Rouvet Lazare is an independent Dassault Systèmes director with strategy, marketing, corporate-management and governance experience. An HEC graduate and IFA/Sciences Po-certified director, she worked at Air France, Saatchi & Saatchi, Publicis and La Poste. She became a Coheris director in2011 and led that software company as chairman and CEO2013–2019, including its turnaround and takeover. Her current own profile identifies an independent Hightech Payment Systems directorship and committee roles.

Olivier Costa de Beauregard represents corporate director Groupe Industriel Marcel Dassault on Dassault Systèmes’ board; the legal director is GIMD rather than the individual in a separate personal voting seat. He has been GIMD CEO since2006 after joining as deputy CEO in2005. He previously worked in France’s financial inspectorate, the prime minister’s office, UAP/AXA and Crédit Commercial de France/HSBC. His own board biography identifies senior French public-administration and policy education and multiple group governance affiliations.

Catherine Dassault is a Dassault Systèmes director. She leads development at Institut de l’Engagement, supporting education, employment and entrepreneurship for young people completing France’s Civic Service program. She studied law and psychology and previously worked in advertising and communications before focusing on medical research and education philanthropy. Her own profile identifies Fondation AP-HP, Green Spark Invest, TCBD & Fils and Fonds de dotation Citadelle affiliations; no personal company subscription is inferred.

Charles Edelstenne founded Dassault Systèmes and is identified in its current own biography as honorary chairman and director. He led the company as manager1981–1993, chairman and CEO1993–2002, then board chairman untilJanuary9,2023. He is also honorary chairman of Groupe Industriel Marcel Dassault and Dassault Aviation, where he previously held senior financial and executive roles. He has a chartered-accountant qualification. These distinct group businesses are not aliases for the software company.

Geneviève Berger is an independent Dassault Systèmes director and its lead director for sustainable development. A physician with a human-biology doctorate, she founded an imaging laboratory at CNRS and Broussais Hôtel-Dieu in1991, headed CNRS2000–2003 and worked at La Pitié-Salpêtrière2003–2008. She later led research at Unilever2008–2014 and Firmenich2015–2021. Her own current board profile also identifies Kerry Group, Institut Curie and Paris-Saclay governance affiliations.

Laurence Daures is Dassault Systèmes’ lead independent director. She is an ESSEC finance professor and CREST-affiliated researcher, with a finance doctorate from HEC Paris and postgraduate degrees from EDHEC, Paris Dauphine and Paris School of Economics. Her work addresses capital-market organization and regulation. She previously led ESSEC’s finance department and taught at ENSAE; her research received the2013 Vega Prize and a2015 derivatives-research award. Her own profile identifies an independent LCL directorship and audit-committee leadership.

Soumitra Dutta is an independent Dassault Systèmes director and scientific-committee chair. He founded and leads Portulans Institute and is a founding general partner of Green Frontier Capital. With a computer-science doctorate, he worked at UC Berkeley, General Electric and INSEAD, where he established eLab and served in dean roles. He subsequently held Cornell business-school leadership2012–2018 and was dean of Oxford’s Saïd Business School2022–2025. The current own biography qualifies the Oxford appointment as former, not current.

Xavier Cauchois is an independent Dassault Systèmes director and audit-committee chair. He spent more than thirty years in audit and consulting as a PwC France partner, working across technology, telecoms, media, healthcare and industry. He led PwC’s European and French technology-sector practice until2009, served on its global audit strategy committee2005–2008 and its French executive committee2013–2016. His current own profile also identifies a Temenos directorship.

Hector Edwards is an OTIF Ventures associate focused on life-sciences investments, joining in2023. The current native directory identifies previous NHS medical practice, Nottingham medical degrees and impact-investment advisory work at New Philanthropy Capital. His company board and observer affiliations are distinct from manager employment.

Alexander Chamberlain is OTIF Ventures Senior Associate, joining in2019 and focused on deep technology and clean technology. His biography describes New Street Research and Seraphim Capital experience, an Edinburgh physical-geography degree, and separately qualified board/observer affiliations.

William Middleton is an OTIF Ventures principal. His biography describes prior Sloane Robinson investment analysis and a separate Technikos biomedical-engineering portfolio-management role. He holds a Melbourne history degree and has Oxford spinout board affiliations; no outside fund is merged into OTIF.

Tania Wilson is OTIF Ventures Principal and CFO. She previously worked in valuation and corporate finance, including PwC. The company biography identifies her as a Chartered Management Accountant with Oxford economics and Cambridge mathematics degrees, joining the manager in early2019.

James Mallinson is an OTIF Ventures partner, having joined inJanuary2018 after managing Oxford’s spinout equity portfolio. His biography describes engineering/software work, Oxford Engineering Science and a Cranfield MBA. University-period shareholdings are distinct from OTIF manager investments.

Ross Hyett is an OTIF Ventures founding partner. The manager biography also identifies him as Ocean Infinity founder and Windsor Private Office senior partner, with entrepreneurial fundraising and prior British Racing Drivers’ Club leadership. Those outside affiliations are not OTIF employees or personal portfolio cash checks.

Christopher Delafield Hall is an OTIF Ventures partner, identified by the exact Companies House legal member record. The current manager biography describes telecommunications, corporate finance and law, including his former Latham & Watkins partnership. The existing Mobio Interactive growth professional Christopher Hall has a different published career and remains separate.

George Robinson is a founding partner of OTIF Ventures and co-founder of Sloane Robinson. His company biography describes Asian equity-research work, Oxford Engineering Science studies and early-stage technology/biotechnology investing. His personal2008 spinout investments are distinguished from later manager transactions.

OTIF Ventures is the current trading name of Oxford Investment Consultants LLP, a UK investment adviser focused on university spinouts in life sciences, deep technology and physical sciences, including neuroscience, artificial intelligence and quantum computing. The firm began operating in 2015 and announced its current branding on 17 April 2026. Its legal LLP, OC396783, was incorporated on 27 November 2014; FCA reference 807688 identifies the same authorised adviser. It advises the Oxford Technology and Innovations EIS Fund (OTIF), supporting companies from seed through follow-on financings and exits, with board and strategic involvement. OTIF is distinct from the University of Oxford Innovation Fund/Mercia vehicles, Oxford Science Enterprises, Oxford Capital and the US infrastructure manager OIC. Investments reflect the adviser’s disclosed fund role; investee financing totals and fund subscription milestones are recorded separately.

Marco Gullà is named as HTH InvestmentAssociate and a member of the team coordinating Zcube’s OpenAccelerator in the February2024 primary launch. HTH is the program’s separate operational partner; this role records a source-proven program affiliation and does not assert statutory Zcube employment. His own public2024 post discusses the program’s conditional SAFE offer, and his own2022 post confirms HTH investor-event jury participation.

Michele Gaiotto, CEO of the separate HTH HealthTechnologyHolding, is a Zcube adviser and coordinator in its February2024 launch. His March22,2024 own program interview identifies him as leading operating partner overseeing women’s-health, central-nervous-system and digital-medicine investments. HTH external partnership does not establish a shared legal manager or that every HTH portfolio company received Zcube cash.

Vittoria Pavoncello is a biotechnologist and neuroscientist. Zcube’s February2024 launch identifies her as Technology Scouting and Investment Specialist and program coordinator. Her2025 LifeSciencesBaltics speaker biography confirms Zcube InvestmentAssociate and managing OpenAccelerator’s women’s-health program. The current2026 Informa investor-conference speaker listing also identifies her as InvestmentAssociate at Zcube ventures; the future conference itself has not yet occurred.

Federica Destro was named Zcube External Innovation and Community Manager and OpenAccelerator coordinator in the February2024 primary launch and her March22,2024 own program interview. Her work encompasses external innovation, life-sciences entrepreneurs and the prior accelerator editions. The currently replaced program site does not establish a complete2026 employment roster.

Elena Zambon is creator of Open Accelerator and chair of Zambon, as identified by the February and September2024 program announcements. This program-creator affiliation is distinct from an asserted Zcube statutory office or personal cash investment. Current ownparent leadership and the separate Zoé foundation identify her leadership roles.

Giovanni Magnaghi was president of Zcube and Zambon CFO in the February27,2024 program launch. The later September2024 Zcube announcement names Andrea D’Alessandro as president. Exact Zcube departure day is unknown. He became ZambonSpA CEO on May2,2024 and remains listed as CEO in current parent leadership; the older CFO portrait page is used for authentic identity only.

Andrea D’Alessandro is identified as president of Zcube in its September24,2024 HyivyHealth financing announcement, superseding the earlier February2024 president. Zambon’s current corporate leadership directory separately identifies him as Chief Compliance Officer. These are separate corporate affiliations; no automatic statutory directorship or personal check is inferred.

Barbara Lucini has held the published role of HR Director of Generali Welion and People Value & Engagement leader for Generali Italia. Her primary professional speaker biography describes experience in organisational culture, change management, leadership development, organisational design, employee welfare, recruitment and employer branding. It records work on inclusion and initiatives supporting girls’ participation in science and technology. The current parent management directory names a sustainability and social-responsibility role; the reviewed Welion HR affiliation is therefore retained as historical rather than automatically assumed current.

Cristina Rustignoli is Generali Italia’s Country General Counsel and a publicly documented member of Generali Welion’s board. Primary Generali transaction disclosure and her professional speaker biography identify this direct Welion governance affiliation alongside board and legal responsibilities elsewhere in the group. Her work includes corporate governance, legal coordination and insurance-company integration. The Welion board affiliation is source-qualified because its exact current term is not published in the company’s reviewed2025 governance model; parent legal duties do not independently establish every subsidiary appointment.

Ivano Bosisio was assigned Operations & Customer Excellence at Generali Welion in the company’s2017 launch announcement. The function supported delivery of the new integrated health and welfare services. His own later professional communication describes Welion’s collaboration with Generali Italia’s Smart Process Automation team using artificial intelligence and optical character recognition to automate processes. The primary role is historically documented; his present Welion appointment, education and a named original portrait remain unverified.

Andrea Mencattini led Generali Welion as chief executive officer at its2017 public launch, according to the company’s primary announcement. His remit centred on integrated welfare, health services, employee benefits and startup-enabled service development. An earlier official Generali biography records his joining the group in1986 and chief executive appointment at Europ Assistance Italia in2006 before leading the Italian insurance business. His Welion affiliation is retained as historical; current appointment and exact tenure end are not asserted.

Cesare Lai previously served as chief executive officer and general manager of Generali Welion. His own primary speaker biography identifies aMarch1,2021 appointment and his oversight of the company’s health and welfare services and employee-benefit insurance operations. The parent’sMay25,2022 announcement names Paolo De Santis as his successor effectiveJune1,2022. The role is historical and is not presented as a current Welion leadership appointment. A genuine named portrait is published in the primary event biography.

Paolo De Santis was appointed chief executive officer and general manager of Generali Welion effectiveJune1,2022, replacing Cesare Lai, according to the parent’s exactMay25,2022 announcement. At appointment he was already Chief Health & Welfare Officer of Generali Country Italia, with extensive group experience in insurance and health. Current company communications name Francesco Bardelli as CEO, so this Welion role is explicitly historical; the exact later succession day is not invented. A separate2019 primary organisational announcement had also named De Santis as Welion executive director during interim management.

Yali Capital is a Bengaluru venture-capital firm backing technology companies building from or for India. It invests in semiconductors, artificial intelligence, robotics, genomics and life sciences, aerospace and surveillance, and advanced manufacturing. Its debut strategy combines seed and Series A investing with later-stage investments in companies with defensible technology and intellectual property. The fund is managed by Yali Partners LLP.

Compliance, audit and regulatory-risk professional with a decade of experience.

Andrea Quarta is identified in his own public professional activity as responsible for Planning and Development at Generali Welion. He represents the company’s work on its health-services ecosystem and customer experience, alongside Health & Welfare Marketing colleagues. His exact ownprofile slug12569b5b distinguishes this insurance-services professional from hospitality and technology professionals with the same name. Education, detailed career history, role start day and an authentic portrait remain unverified.

Over 35 years of deep-tech experience, including entrepreneurship and investing.

Venture operations professional.

Deep-tech investor with 30 years of experience in multinational technology companies and startups. Published nickname Karthik.

Holds a Ph.D. in computational biology and has nearly a decade of experience in the US research ecosystem.

Finance professional with more than 15 years across finance and operations functions.

Chairman of Florintree Advisors with private-equity and corporate leadership experience.

Creative director and communications professional with 14 years of marketing experience.

Technology entrepreneur and investor with more than 15 years in AI, media technology and education technology.

Finance and operations professional with more than 20 years of startup finance and regulatory-compliance experience.

Francesco Gelosa works in health and welfare marketing at Generali Welion. Primary2024 programme material identifies him within the company’s Health & Welfare Services and Marketing function, and Welion’s2025 business-cascading communication names his participation in the Attiva Welfare discussion covering health services and home assistance for caregivers and vulnerable people. His own professional profile confirms the company affiliation and study at MIB Trieste School of Management. Exact current managerial seniority and appointment dates are not inferred from secondary organisation charts.

Giulia Franceschi is responsible for Medical Network Management at Generali Welion, as named in the company’s own2025 event announcement and2026 communications. Her public work concerns the healthcare-provider network, integration of medical appointment systems and digital access to care for insured clients. Her own professional profile identifies Generali Welion and business-school education at New York University’s Stern School of Business; broader biographical details and an original named portrait remain unverified.

Barbara Ambrogioni heads Health & Welfare Services and Marketing at Generali Welion. She has more than20years of experience in health and welfare, insurance brokerage and human-resources consulting. Since joining Generali in2018 she has helped define B2B and retail welfare services for the open market and supported group insurers’ health and protection offerings. Her primary professional biography records economics and actuarial studies at Sapienza University of Rome and a master’s in Insurance & Risk Management at MIB School of Management. Welion’s2026 company event communications confirm her current service and marketing responsibilities.

Nicola Meliddo is the named chairman and internal member of Generali Welion’s Organismo di Vigilanza in its current official governance disclosure. The supervisory body oversees implementation and effectiveness of the company’s organisational and compliance model under Italian Legislative Decree231/2001. The2025 model describes the oversight system and internal-control reporting responsibilities. A wider professional career, education and genuine portrait are not published in the reviewed primary disclosure.

Gianluca Perin is chairman of Generali Welion and Country General Manager of Generali Italia, as identified in the parent’s current official biography. He studied business economics at Università Bocconi. His career included human-resources leadership at RCS, Mondadori and Il Sole24Ore before joining Generali in2012 as HR director for Alleanza Toro. He became Generali Italia’s Chief HR & Organization Officer in2013 and Country General Manager inSeptember2022. This is a source-proved Welion governance appointment; other parent managers are not automatically assigned to Welion.

Francesco Bardelli leads Generali Welion as chief executive officer and general manager and is Generali Italia’s Chief Health & Welfare and Broker Management Officer. His responsibilities connect health and accident insurance, integrated welfare services and strategic development. Primary speaker material records engineering studies at Politecnico di Milano and an MBA at SDA Bocconi, earlier international transformation work at McKinsey and SIA, and his2013 entry into Generali. He subsequently worked on Italian insurer integration, business transformation, connected insurance at Generali jeniot and the Cattolica integration. Welion’s2026 company communications confirm his current CEO appointment; an older2022 release appointed Paolo De Santis, so Bardelli’s exact succession day remains unclaimed.

Zcube is Zambon’s life-sciences research venture, established in 2003, supporting innovative startups in respiratory conditions, neurodegenerative disease and women’s health. The current parent’s own legal disclosure identifies ZCube S.r.l., single-shareholder company, fiscalcode03018160246 and Milan registry1691719, based in Bresso. Its own2024 Open Accelerator regulations identify the contracting corporate sponsor as ZetaCube S.r.l.; Zcube is the published corporate brand. Zambon Company S.p.A., Zambon S.p.A., Zcube and the OpenZone campus are distinct entities or units; Open Accelerator is a program established2016 and operated/sponsored by Zcube, not a separate verified investment manager or LP fund. The current accelerator site explicitly names Zcube S.r.l. as data controller and states the program will be back soon; it does not publish a current complete team roster. Published2024 sources identify its program team, while dated leadership records distinguish former president Giovanni Magnaghi from later president Andrea D’Alessandro. The program’s CNS/digital-health strategy and actual2018 investments in Parkinson movement-monitoring MobileGaitLab/Portabiles, essential-tremor Vilimball, multiple-sclerosis diagnostics Prindex and machine-learning respiratory monitoring LungPass establish neurotechnology/AI/deep-technology relevance. Clinical performance statements remain company/program claims, not independent validations. Its actualSeptember24,2024 financing announcement identifies Zcube as lead of HyivyHealth’s CAD2million round; individual ticket is undisclosed. The same-year cohort announcement promises up-to-EUR100000 SAFE investments after evaluation, which does not prove disbursement to every selected startup. The corporation also reports investments in unnamed external venture funds; their exact vehicles, commitments and closes remain unverified. RegisteredEUR320000 corporate share capital is not a fundraising round or venture fund close, and program award ceilings are not pooled-fund sizes. No separate verified Zcube corporate financing or LP closing has been found. Parent corporate roster is not copied into this subsidiary. The authentic Zcube own-site wordmark is preserved; named public portraits are included only when individually authenticated.

Aidiom is a Norwegian deep-technology investor focused on early-stage business-to-business software using applied artificial intelligence. It invests in the European Economic Area and works with founders from initial company formation through growth and exits, offering board involvement, company-building experience and financing support. Its stated ticket range is USD 100,000 to USD 1 million. Alongside direct startup investments, its published portfolio includes investments in other venture managers and funds.

Meneldor is a Dutch life-sciences investment firm that invests its own capital and organizes co-investments in European biotech and pharmaceutical companies. It evaluates opportunities from early development through Phase III, emphasizing novel therapies, strong intellectual property, unmet medical needs and a feasible clinical-development path. Its evergreen Dutch cooperative model lets co-investors participate through selected special-purpose vehicles on negotiated terms. The team supports portfolio companies with scientific assessment, drug development, manufacturing, strategy and financing.

PAACS Invest is a privately owned Norwegian investment company and family office focused on active investments in healthcare and technology, with an emphasis on sustainability and precision health. It supports early-stage life-sciences companies with capital and company-development advice. Issuer materials identify investments in Hemispherian, EXACT Therapeutics, PubGene and RemovAid. The Norwegian legal company is PAACS Invest AS.

Yara Growth Ventures is Yara International’s corporate venture capital organization, investing globally in agriculture and clean hydrogen. It backs startups developing science and technology for food production, agricultural finance, biological inputs, industrial software, hydrogen and ammonia infrastructure. It also invests as a limited partner in specialist venture funds. The team typically targets an initial investment of about USD 3 million and supports companies through industry expertise, field trials and introductions to Yara’s network. Yara Growth Ventures AS is a separately registered Norwegian entity within the Yara group.

PwC-trained chartered accountant with manufacturing, fertilizer and technology finance experience.

Clinical pathologist, former AML laboratory entrepreneur and Heran Partners founding partner advising on life-sciences investing.

Venture investor and company builder in agriculture, green chemistry, advanced materials and enterprise software; trained in physical chemistry.

Chemistry, manufacturing and controls specialist with more than 20 years in Synthon research and development leadership.

Environmental-science and data-analytics professional with marine ecosystem management and mathematics degrees.

Ardena COO and ChemConnection founder with experience building drug-development and manufacturing businesses.

Life-sciences and health-technology leader supporting portfolio strategy, governance, partnerships and international growth.

Precision-health investor with an Oxford DPhil in genetics and neuroscience and earlier investment-banking experience at Morgan Stanley, Altium Capital and Arctic Securities. Her PAACS investor/co-chair title is self-described in an April 2023 interview; it is distinct from the current legally registered chair.

Henlius senior vice president and chief business officer with biopharmaceutical partnerships, manufacturing and business-development experience.

Cambridge-trained biochemist with crop-protection and disease-resistant crop development experience.

Christoph Bartoschek is named by EITHealth as the Aescuvest contact for its2021 crowdfunding investment-readiness programme. A2025 PIURImaging issuer release names him as investment principal at AescuvestCapitalPartners, the related but distinct fund-manager business. The Aescuvest platform affiliation is source-qualified historical; no automatic current platformemployment or legalACPmanagerrole is created here. A genuine individual portrait remains unverified. ACP-specific affiliation: Christoph Bartoschek is identified as Investment Principal in ACP’s January2025 launch release and PIURImaging’s July2025 financing announcement. His own current public professional profile names ACPHealthtechManagementGmbH. This is distinct from his historical Aescuvest platform programme-contact work.

David Cubbin is an investor and business operator. His own2025 announcement records joining Aescuvest as a partner. His2026 announcement describes founding the separate FerysCapital with SebastianGührs and places his Aescuvest partner work in his prior career alongside ChallengerEMEA and CureCapital. This profile preserves the actual historicalAescuvestappointment without claiming ongoing2026tenure or mergingFerys with Aescuvest. An authentic individual portrait remains unverified. ACP-specific qualified affiliation: Patrick Pfeffer’s public reply to DavidCubbin’s2025 Aescuvest appointment announcement welcomes him to work at both Aescuvest and ACPHealthtech. That supports an investment-team collaboration, but does not disclose an ACP-specific legal partner appointment. David’s2026 FerysCapital launch is separate. This record uses a historical collaborator title, not a guessed currentACPpartnerrole.

Sebastian Gührs is a healthcare venture investor. Primary2023 Neteera financing announcements and a2024 conference biography name him as partner and head of investment at Aescuvest. In his2026 self-authored announcement, he refers to his past years at Aescuvest and launches the separate FerysCapital with DavidCubbin. This Aescuvest role is retained as a qualified historical affiliation rather than asserted as current. The authentic original portrait is extracted from the2024 Carmo organizer speaker biography. ACP-specific historical affiliation: The2024 Carmo organizer biography labels Sebastian Gührs Partner and Head of Investment at ACPHealthtech/Aescuvest. Subsequent2026 first-person announcements describe founding the separate FerysCapital with DavidCubbin and priorAescuvestcareer. His historical ACP title is qualified rather than asserted as ongoing2026 employment.

Olivier Gracia identifies himself in his April2026 own biography as CFO at Aescuvest and separately CFO and general partner at ACPHealthTech. His career includes product and growth work at Eurosport and WebMD Europe, followed by information management and marketing work at Aescuvest. The current CFO role supersedes older directoryCMO wording; ACPHealthTech is a distinct legal manager. His portrait is published on his own current biography. ACP-specific affiliation: Olivier Gracia’s signed April2026 biography and venture page identify him as CFO and general partner at ACP HealthTech, separately from CFO at the Aescuvest platform. The named ownlinks bridge this actualACPmanagerdomain. These distinct roles are retained without migrating either organization’s investment checks.

Patrick Pfeffer founded Aescuvest in2014 and is named on its current ownsite as managing partner and legal managing director. He previously worked in health-media and digital strategy, including WebMD/Medscape European expansion. His primary interview describes his healthcare crowdfunding approach; his2025 personal announcement distinguishes the Aescuvest deal-by-deal platform from the separately launched ACPHealthtech fund business. The genuine portrait is from his dated2015 firsthand interview, not presented as a newly photographed2026 image. ACP-specific affiliation: Patrick Pfeffer is named as managing partner in ACP’s own January2025 launch announcement. His own launch post describes forming this fund manager separately from the Aescuvest deal-by-deal platform, and his later first-close announcement confirms actual LP backing without disclosing fund size or closing day.

Aescuvest is a European healthtech investment platform operated by Aescuvest GmbH, founded in2014 and registered in Frankfurt am Main as HRB100439 (LEI529900TMDM5YV1UUSF34). It sources, evaluates and structures individual financings and co-invests alongside qualified business angels, family offices and corporate partners through dedicated deal-specific SPVs. The current platform emphasizes remote monitoring, diagnostics and personalized medicine, including AI-assisted diligence and medical technology. It is distinct from a blind-pool LP fund: investors select specific opportunities and receive each vehicle’s disclosures. Current published leadership identifies managing director/managing partner Patrick Pfeffer; Olivier Gracia’s April2026 own biography identifies him as CFO. Historical investment colleagues are qualified separately. Aescuvest International GmbH historically acted as a tied-agent/platform operator in prospectus-based crowdfunding, rather than automatically being the legal issuer or fund manager. Related ACP Healthtech Management GmbH is a distinct AIFM with its own legal fund; that fund is not attributed to this platform without exact management evidence. Selected portfolio relationships and platform-facilitated financings do not imply an undisclosed corporate balance-sheet ticket.

U2V is a European venture investment platform backing pre-seed and seed companies commercialising university and research discoveries. Its three investment themes are AI and novel computing, industrial technology and clean technology: it supports both AI applications and enabling systems such as semiconductors, quantum computing and photonics, alongside robotics, automation and resource-efficient industry. The team combines prior venture investing with engineering, scientific research and company-building experience. Its first fund is U2V Fund I GmbH & Co. KG; the own legal and SFDR disclosures identify Motu Ventures Management GmbH (HRB 156547 B, LEI 894500S3LLY84ZI0DX02) as the registered alternative investment fund manager. U2V is the public investment brand and is not automatically merged with Earlybird Venture Capital or assigned Earlybird-X’s historical corpus and holdings.

Andreas Werner is a U2V venture partner and technology entrepreneur. He co-founded industrial location-systems company Agilion, which Siemens acquired, and subsequently supported its RTLS technology.

Moritz von Klot is a U2V principal whose investing experience spans Earlybird-X, university commercialisation and climate technology. He studied mechanical engineering and finance.

LSI Zeta is Life Science Invest’s sixth Nordic life-science co-investment company. It pools capital from business angels with biotechnology, medical technology and entrepreneurial experience to invest in early-stage Nordic life sciences, health technology and medical technology companies. The vehicle announced EUR2.9 million raised from 35 angels in January 2026 and aims to build a portfolio of around ten companies, supporting them with expertise as well as financing. Published investments include CubaseBio, Mesenkia Therapeutics, Solid IO, StemSight and RAB Diagnostics. It is a distinct investing vehicle under the Life Science Invest network; its published angel shareholders are members and investors rather than employees.

Life Science Invest is a Nordic life-science business angel network founded in Sweden by Ann-Charlotte Beckman and Magnus Klaesson. It brings together experienced entrepreneurs and industry specialists through separate co-investment companies, including LSI Alpha, Beta, Gamma, Scale Up LSI (Delta), Epsilon and Zeta. The network focuses on early-stage life sciences, medical technology and health technology businesses and combines capital with commercial, scientific and operational expertise. Its investment committee evaluates clinical or customer needs, intellectual property, scalability, business models and the skills each founding team requires. The network also runs investor education and supports portfolio companies through its members’ contacts and experience.

Nurse and market economist with experience building Netdoktor, healthcare operations, entrepreneurship and life-science angel investing.